AMPK agonists and methods of use thereof

By providing the compounds of formula (I) to directly activate AMPK, the shortcomings of existing AMPK activators in the treatment of mitochondrial diseases are solved, and effective treatment of primary and secondary mitochondrial diseases is achieved, especially in the case of mitochondrial dysfunction Improvement.

CN119013256APending Publication Date: 2024-11-22EVVIA THERAPEUTICS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202380030086.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-25
Filing Date
2023-01-24
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing AMPK activators are insufficient in the treatment of primary and secondary mitochondrial diseases, especially in cases with mitochondrial dysfunction, and existing supportive treatments lack the efficacy and cannot cure the disease.

Method used

A compound of formula (I) and its pharmaceutically acceptable salts, solvates, hydrates, co-crystals or prodrugs are provided for direct activation of AMPK, independent of the mechanism of AMP, for the treatment of mitochondrial dysfunction.

Benefits of technology

The compound is able to effectively activate AMPK, improve mitochondrial function, and provide new treatments for primary and secondary mitochondrial diseases, improving therapeutic effects, especially in the presence of mitochondrial dysfunction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013256A_ABST
    Figure CN119013256A_ABST
Patent Text Reader

Abstract

Compounds and methods of using the compounds to treat conditions ameliorated by AMPK activation are provided. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure generally relates to compounds and methods of using the same to treat conditions ameliorated by AMPK activation.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application is an international application claiming priority to U.S. Provisional Application No. 63 / 302,942 filed on January 25, 2022, which is incorporated herein by reference in its entirety. Background Art

[0004] Previously studied drug candidates are traditional AMP-dependent AMPK activators whose mechanism of action requires AMP elevation through RC inhibition (e.g., metformin, resveratrol) or conversion to AMP mimetics (e.g., AICAR). Indirect mechanisms involving RC inhibition are not applicable in cases with underlying mitochondrial dysfunction, while AMP-dependent AMPK activation leads to activation of other AMP-regulated enzymes, exacerbating pleiotropic effects. In addition, previous studies have identified direct, AMP-independent AMPK agonists for the treatment of diabetes, obesity, and metabolic syndrome.

[0005] Primary mitochondrial diseases are a clinically heterogeneous group of conditions that are often progressive, multisystemic, and associated with high childhood mortality. They are caused by genetic defects in the mitochondrial respiratory chain (RC), leading to increased production of reactive oxygen and nitrogen species (ROS and RNS) and deficiencies in overall energy production. These resulting metabolic imbalances can lead to cellular damage and ultimately cell death.

[0006] There is currently no definitive treatment for primary mitochondrial diseases. Supportive care is the only available option, including treatment of specific symptoms (e.g., diabetes, heart disease, and ptosis) and a “mitochondrial cocktail” consisting of vitamin cofactors and antioxidants. Unfortunately, meta-analyses have shown that existing supportive interventions lack efficacy, highlighting the need for new treatment approaches.

[0007] Secondary mitochondrial diseases also exhibit mitochondrial dysfunction, but unlike primary mitochondrial diseases, they are not caused by genes related to the mitochondrial respiratory chain. Secondary mitochondrial diseases (such as Parkinson's disease or Alzheimer's disease) are acquired mitochondrial abnormalities caused by other diseases, conditions or environmental factors that indirectly damage mitochondria. Therefore, any treatments for primary mitochondrial diseases are also expected to benefit conditions and disorders associated with secondary mitochondrial dysfunction, including neurodegenerative disorders, neuromuscular disorders and muscle wasting disorders.

[0008] There is a need in the art for new treatments for primary and secondary mitochondrial diseases. The present disclosure addresses this need in the art. Summary of the invention

[0009] In one aspect, the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

[0010]

[0011] Wherein in formula (I):

[0012] X1 for CR 4a or N;

[0013] X2 for CR 4b or N;

[0014] R1 is selected from

[0015] R2 is selected from H, C 1-3 Alkyl, -CF3 and halide;

[0016] R3 at each occurrence is independently selected from halo, -CN, -N(R 10 2. C 1-10 Alkyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkyloxy, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 Heterocycloalkenylalkyl, aryl and heteroaryl, wherein C 1-10 Alkyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 The heterocycloalkenyl alkyl, aryl or heteroaryl groups are unsubstituted or substituted with one to three radicals selected from deuterium, halo, C 1-6 Alkyl, C 3-6 Substitution by substituents of cycloalkyl, -OR5 and -OCOR7;

[0017] R 4a is independently selected at each occurrence from H, halo, C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl and C 4-10 Cycloalkylalkyl, wherein C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl or C 4-10 Cycloalkylalkyl is unsubstituted or substituted with one to three halogen substituents;

[0018] R 4b independently selected at each occurrence from H, C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl and C 4-10 Cycloalkylalkyl, wherein C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl or C 4-10 Cycloalkylalkyl is unsubstituted or substituted with one to three halogen substituents;

[0019] R5 at each occurrence is independently selected from H, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl and C 4-10 Cycloalkylalkyl, wherein C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl or C 4-10 Cycloalkylalkyl is unsubstituted or substituted with one to three halogen substituents;

[0020] R6 at each occurrence is independently selected from H, C 1-6 Alkyl and C 3-6 Cycloalkyl;

[0021] R7 is independently selected at each occurrence from C 1-10 Alkyl, C 3-7 Cycloalkyl and C 4-12 Alkylcycloalkyl, wherein C 1-10 Alkyl, C 3-7 Cycloalkyl or C 4-12 Alkylcycloalkyl is unsubstituted or substituted by one to three groups selected from halogen, C 1-10Alkyl and -NR 12 , R 12 Substituents are substituted;

[0022] R8 is selected from H, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-10 Heterocyclic group, C 4-12 Alkyl heterocyclic group, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 Heterocycloalkenylalkyl, aryl, heteroaryl, Among them C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-10 Heterocyclic group, C 4-12 Alkyl heterocyclic group, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 Heterocycloalkenylalkyl, aryl or heteroaryl is unsubstituted or substituted with one to three substituents selected from deuterium, halo and -OR5;

[0023] R 10 independently selected at each occurrence from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 4-12 Alkylcycloalkyl, and C 3-10 Heterocyclic group, wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, C 4-12 Alkylcycloalkyl or C 3-10 The heterocyclic group is unsubstituted or substituted by one to three radicals selected from deuterium, halogen, C 1-6 Alkyl and C 3-6 Substitution of cycloalkyl groups;

[0024] R 11 In each occurrence, independently selected from -OR 12 and -N(R 12 )2;

[0025] R 12 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-10 Haloalkoxy and C 3-6 Cycloalkyl;

[0026] n is an integer from 0 to 3;

[0027] p is an integer from 1 to 5;

[0028] q is an integer from 0 to 5;

[0029] r is an integer from 1 to 5;

[0030] s is an integer from 1 to 5;

[0031] A is selected from phenyl, pyridyl, pyrimidinyl, pyridazinyl and the following 5-membered heterocyclic rings:

[0032]

[0033] The premise is that the compound of formula (I) is not

[0034] In some embodiments, X1 is CR 4a In some embodiments, R 4a is H, Cl or F. In some embodiments, X2 is N or CR 4b , where R 4b In some embodiments, R2 is H. In some embodiments, R2 is halo. In some embodiments, R2 is Cl or F. In some embodiments, in some embodiments, R6 is H.

[0035] In some embodiments, A is selected from:

[0036]

[0037] In some embodiments, R6 is H.

[0038] In some embodiments, the compound of formula (I) is a compound of formula (10), formula (11), formula (12), formula (13), formula (14), formula (15), formula (16), or formula (17), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof. In some embodiments, R1 is In some embodiments, the compound of formula (I) is a compound of formula (100), formula (110), formula (120), formula (130), formula (140), formula (150), formula (160), or formula (170), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof.

[0039] In some embodiments, R1 is In some embodiments, the compound of formula (I) is a compound of formula (200), formula (210), formula (220), formula (230), formula (240), formula (250), formula (260), or formula (270), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof.

[0040] In some embodiments, R1 is In some embodiments, the compound of formula (I) is a compound of formula (300), formula (310), formula (320), formula (330), formula (340), formula (350), formula (360), or formula (370), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof. In some embodiments, the compound is selected from:

[0041]

[0042] In some embodiments, R1 is In some embodiments, the compound of formula (I) is a compound of formula (400), formula (410), formula (420), formula (430), formula (440), formula (450), formula (460), or formula (470), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof.

[0043] In some embodiments, R1 is In some embodiments, the compound of formula (I) is a compound of formula (500), formula (510), formula (520), formula (530), formula (540), formula (550), formula (560), or formula (570), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof.

[0044] In some embodiments, R1 is In some embodiments, the compound of formula (I) is a compound of formula (600), formula (610), formula (620), formula (630), formula (640), formula (650), formula (660), or formula (670), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof.

[0045] In some embodiments, R1 is In some embodiments, the compound of formula (I) is a compound of formula (700), formula (710), formula (720), formula (730), formula (740), formula (750), formula (760), or formula (770), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof.

[0046] In some embodiments, R1 is In some embodiments, the compound of Formula (I) is a compound of Formula (800), Formula (810), Formula (820), Formula (830), Formula (840), Formula (850), Formula (860), or Formula (870), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof.

[0047] In some embodiments, R1 is In some embodiments, the compound of formula (I) is a compound of formula (900), formula (910), formula (920), formula (930), formula (940), formula (950), formula (960), or formula (970), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof.

[0048] In some embodiments, R 10 Selected from H, methyl, ethyl, -CD3, n-butyl, In some embodiments, R 11 Selected from In some embodiments, p is 2 or 3. In some embodiments, R3 is selected from -F, -CN, ethyl, Optionally

[0049] In some embodiments, R3 is selected from Optionally selected from In some embodiments, q is 0 or 1. In some embodiments, r is 2 or 3. In some embodiments, s is 1. In some embodiments, R 12 Selected from methyl, ethyl, -OCF3 and In some embodiments, R8 is selected from H, methyl, ethyl, isopropyl, n-butyl, tert-butyl,

[0050]

[0051] In some embodiments, R8 is selected from H, methyl, ethyl, n-butyl, In some embodiments, R8 is selected from H, methyl, and ethyl.

[0052] In some embodiments, the compound of Formula (I) is selected from a compound having a formula selected from Formulas 1001-1114, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof.

[0053] In some embodiments, the compound of formula (I) is selected from a compound having a formula selected from formula 1003, 1007, 1024, 1044, 1077, 1078, 1081, 1084, 1088, 1112, 1113, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof.

[0054] In some embodiments, the compound of formula (I) is selected from a compound having a formula selected from formula 1001, 1006, 1008, 1010, 1013, 1014, 1016, 1017, 1018, 1022, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof.

[0055] In some embodiments, the compound of formula (I) is selected from a compound having a formula selected from formula 1003, 1009, 1011, 1015, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof.

[0056] In some embodiments, A is a 5-membered heterocyclic ring, and R1 is R8 is not H.

[0057] In some embodiments, the compound of formula (I) is selected from a compound having a formula selected from formulas 1001-1114, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof. In some embodiments, the compound of formula (I) is selected from a compound having a formula selected from formulas 1003, 1007, 1009, 1011, 1015, 1019, 1023, 1024, 1025, 1026, and 1078, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof. In some embodiments, the compound of formula (I) is selected from a compound having a formula selected from formulas 1001, 1006, 1008, 1010, 1013, 1014, 1016, 1024, 1017, 1018, and 1022, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof. In some embodiments, the compound of Formula (I) is selected from a compound having a formula selected from Formula 1003, 1009, 1011 and 1015, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof.

[0058] In some embodiments, in Formula (I), when A is a 5-membered heterocyclic ring and R1 is When R8 is not H.

[0059] On the other hand, the present disclosure provides a pharmaceutical preparation comprising a compound having any one of Formula (I), Formulas (10) to (17), Formulas (20) to (26), Formulas (100) to (190), Formulas (200) to (270), Formulas (300) to (370), Formulas (400) to (470), Formulas (500) to (570), Formulas (600) to (670), Formulas (700) to (770), Formulas (800) to (870), Formulas (900) to (970), and Formulas 1001 to 1114.

[0060] In another aspect, the present disclosure provides a method for treating a patient suffering from mitochondrial dysfunction. In some embodiments, the method comprises identifying mitochondrial dysfunction in an individual; and administering to the patient a compound having any one of Formula (I), Formulas (10) to (17), Formulas (20) to (26), Formulas (100) to (190), Formulas (200) to (270), Formulas (300) to (370), Formulas (400) to (470), Formulas (500) to (570), Formulas (600) to (670), Formulas (700) to (770), Formulas (800) to (870), Formulas (900) to (970), and Formulas 1001 to 1114.

[0061] In another aspect, the present disclosure provides a method for treating a patient suffering from mitochondrial dysfunction. In some embodiments, the method comprises administering to the patient a therapeutically effective amount of a compound having any one of Formula (I), Formulas (10) to (17), Formulas (20) to (26), Formulas (100) to (190), Formulas (200) to (270), Formulas (300) to (370), Formulas (400) to (470), Formulas (500) to (570), Formulas (600) to (670), Formulas (700) to (770), Formulas (800) to (870), Formulas (900) to (970), and Formulas 1001 to 1114.

[0062] In some embodiments, the mitochondrial dysfunction is a primary mitochondrial dysfunction. In some embodiments, the primary mitochondrial dysfunction is selected from the group consisting of autosomal dominant optic atrophy (ADOA), Alpers-Huttenlocher syndrome (nDNA defect), ataxic neuropathy syndrome (nDNA defect), Barth syndrome / lethal infantile cardiomyopathy (LIC), coenzyme Q deficiency, complex I, complex II, complex III, complex IV and complex V deficiency (single deficiency or any combination of deficiency), chronic progressive external ophthalmoplegia (CPEO), diabetes and deafness, Kearns-Sayre syndrome (mtDNA defect), leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate (LBSL-leukodystrophy), Leigh syndrome (mtDNA and nDNA defects), Leber hereditary optic neuropathy (LHON ), Luft disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke syndrome (MELAS) (mtDNA defect), mitochondrial enoyl-CoA reductase protein-associated neurodegeneration (MEPAN), myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial recessive ataxia syndrome (MIRAS), mtDNA deletion syndrome, mtDNA depletion syndrome, mtDNA maintenance disorder, mtDNA / RNA translation defect, mitochondrial tRNA synthetase defect, mitochondrial myopathy, mitochondrial neurogastroenteric encephalopathy syndrome (MNGIE), neurogenic myasthenia, ataxia, and retinitis pigmentosa (NARP), Pearson syndrome, pyruvate dehydrogenase complex deficiency (PDCD / PDH), DNA polymerase gamma deficiency (POLG), pyruvate carboxylase deficiency, and thymidine kinase 2 deficiency (TK2).

[0063] In some embodiments, the mitochondrial dysfunction is a secondary mitochondrial dysfunction. In some embodiments, the secondary mitochondrial dysfunction is selected from the group consisting of: age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and other dementias, Friedreich's ataxia (FA), Huntington's disease (HD), motor neuron disease (MND), N-glycanase deficiency (NGLY1), organic acidemias, Parkinson's disease (PD) and PD-related disorders, prion diseases, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA), Becker muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, Em ery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, Charcot-Marie-Tooth disease, congenital myopathies, distal myopathies, endocrine myopathies (hyperthyroid myopathy, hypothyroid myopathy), giant axonal neuropathy, hereditary spastic paraplegia, inflammatory myopathies (dermatomyositis, inclusion body myositis, polymyositis), metabolic myopathies, neuromuscular junction disorders, autism, cancer, diabetes, metabolic syndrome, chronic fatigue syndrome, inflammatory disorders, arthritis, aging, and mitochondrial epilepsy (epilepsy secondary to primary mitochondrial disease).

[0064] In some embodiments, a compound having any one of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), and (1001 to 1114 is administered in a pharmaceutical formulation. In some embodiments, the pharmaceutical formulation comprises the compound and at least one selected from a binder, a lubricant, a buffer, and a coating. In some embodiments, the compound is administered orally. In some embodiments, the compound is administered daily for at least one week.

[0065] In some embodiments, the method further comprises evaluating the efficacy of the compound in the individual.

[0066] In some embodiments, the compound having any of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), and Formula 1001 to 1114 is administered orally, subcutaneously, intravenously, intraperitoneally, nasally, dermally, by intravitreal injection, or by inhalation. BRIEF DESCRIPTION OF THE DRAWINGS

[0067] Figure 1 Shown are structures of non-limiting examples of compounds of the present disclosure.

[0068] Figure 2 Shown are structures of non-limiting examples of compounds of the present disclosure.

[0069] Figure 3 Shown are structures of non-limiting examples of compounds of the present disclosure.

[0070] Figure 4 Shown are structures of non-limiting examples of compounds of the present disclosure.

[0071] Figure 5 Shown are structures of non-limiting examples of compounds of the present disclosure.

[0072] Figure 6 Shown are structures of non-limiting examples of compounds of the present disclosure.

[0073] Figure 7 Shown are structures of non-limiting examples of compounds of the present disclosure.

[0074] Figure 8 Shown are structures of non-limiting examples of compounds of the present disclosure.

[0075] Fig. 9 Shown are structures of non-limiting examples of compounds of the present disclosure. DETAILED DESCRIPTION

[0076] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs.All patents and publications mentioned herein are incorporated by reference in their entirety.

[0077] definition

[0078] The terms "administer," "administration," or "administering" as used herein refer to (1) providing, giving, administering, and / or prescribing according to the present disclosure by or under the guidance of a health practitioner or their authorized agent; and / or (2) placing, taking, or consuming by a mammal according to the present disclosure.

[0079] As used herein, the terms "co-administration," "co-administering," "administered in combination with," "administering in combination with," "simultaneous," and "concurrently" encompass the administration of two or more active pharmaceutical ingredients to a subject such that both active pharmaceutical ingredients and / or their metabolites are present in the subject at the same time. Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both active pharmaceutical ingredients are present. Simultaneous administration in separate compositions and administration in a composition in which both agents are present are preferred.

[0080] The terms "active pharmaceutical ingredient" and "drug" include, but are not limited to, the compounds described herein, and more specifically, compounds of any of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), and Formulas 1001 to 1114, and the features and limitations described herein.

[0081] As used herein, the terms "patient," "subject," and "individual" are used interchangeably.

[0082] The term "in vivo" refers to events occurring within the body of a subject.

[0083] The term "in vitro" refers to events that occur outside the body of a subject. In vitro assays include cell-based assays that employ living or dead cells, and may also include cell-free assays that do not use intact cells.

[0084] The term "effective amount" or "therapeutically effective amount" refers to an amount of a compound or combination of compounds described herein that is sufficient to achieve the intended application (including but not limited to disease treatment). The therapeutically effective amount may vary depending on the intended application (in vitro or in vivo) or the subject and disease condition being treated (e.g., the subject's weight, age, and gender), the severity of the disease condition, the mode of administration, etc., and these factors can be easily determined by a person of ordinary skill in the art. The term also applies to doses that induce a specific response in target cells (e.g., increased sensitivity to apoptosis). The specific dose will vary depending on the specific compound selected, the dosing regimen to be followed, whether the compound is administered in combination with other compounds, the time of administration, the tissue to which it is administered, and the physical delivery system that carries the compound.

[0085] The term "therapeutic effect" as used herein includes therapeutic benefit and / or prophylactic benefit. Prophylactic effect includes delaying or eliminating the appearance of a disease or disorder, delaying or eliminating the onset of symptoms of a disease or disorder, slowing, stopping or reversing the progression of a disease or disorder, or any combination thereof.

[0086] The term "QD", "qd" or "qd" means once a day, once a day or once a day. The term "BID", "bid" or "bid" means twice a day, twice a day or twice a day. The term "TID", "tid" or "tid" means three times a day, three times a day or three times a day. The term "QID", "qid" or "qid" means four times a day, four times a day or four times a day.

[0087] The term "pharmaceutically acceptable salt" refers to salts derived from various organic and inorganic counterions known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Preferred inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Preferred organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins. Specific examples include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt is selected from ammonium salts, potassium salts, sodium salts, calcium salts and magnesium salts. The term "co-crystal" refers to a molecular complex derived from a variety of co-crystal formers known in the art. Unlike salts, co-crystals generally do not involve hydrogen transfer between the co-crystal and the drug, but rather involve intermolecular interactions between the co-crystal former and the drug in the crystal structure, such as hydrogen bonding, aromatic ring stacking or dispersion forces.

[0088] "Pharmaceutically acceptable carriers" or "pharmaceutically acceptable excipients" are intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and inert ingredients. The use of such pharmaceutically acceptable carriers or pharmaceutically acceptable excipients for active pharmaceutical ingredients is well known in the art. Unless any conventional pharmaceutically acceptable carrier or pharmaceutically acceptable excipient is incompatible with the active pharmaceutical ingredient, its use in the therapeutic compositions of the present disclosure is contemplated. Other active pharmaceutical ingredients (e.g., other drugs disclosed herein) may also be incorporated into the described compositions and methods.

[0089] As used herein, the terms "treat," "treatment," and / or "treating" may refer to the management of a disease, disorder, or pathological condition, or a symptom thereof, with the goal of curing, ameliorating, stabilizing, and / or controlling the disease, disorder, pathological condition, or a symptom thereof. More specifically, with respect to control of a disease, disorder, or pathological condition, "control" may include the absence of progression of the condition, as assessed by response to the methods described herein, wherein such response may be complete (e.g., causing remission of the disease) or partial (e.g., alleviation or amelioration of any symptom associated with the condition).

[0090] As used herein, the terms "modulate" and "modulation" refer to changes in the biological activity of a biological molecule (e.g., a protein, gene, peptide, antibody, etc.), wherein such changes may involve an increase in the biological activity of the biological molecule (e.g., increased activity, agonism, activation, expression, upregulation, and / or increased expression) or a decrease in the biological activity (e.g., decreased activity, antagonism, inhibition, inactivation, downregulation, and / or decreased expression). In some embodiments, the biological molecules modulated by the methods and compounds of the present disclosure to achieve treatment may include Mcl-1 oncoprotein and Bcl-2 oncoprotein.

[0091] As used herein, the term "prodrug" refers to a derivative of a compound described herein, the pharmacological effect of which is produced by conversion to an active compound by chemical or metabolic processes in vivo. Prodrugs include compounds in which an amino acid residue or a polypeptide chain of two or more (e.g., two, three, or four) amino acid residues is covalently linked to a free amino group, hydroxyl group, or carboxylic acid group of a compound of any of Formulas (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), or (1001 to 1114 via an amide bond or an ester bond. Amino acid residues include, but are not limited to, the 20 naturally occurring amino acids generally designated by one or three letter symbols, but also include, for example, 4-hydroxyproline, hydroxylysine, desmosine, isodesmosine, 3-methylhistidine, β-alanine, γ-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine, and methionine sulfone.

[0092] Other types of prodrugs are also included. For example, free carboxyl groups can be derived into amides or alkyl esters (for example, methyl esters and acetoxymethyl esters). Prodrug esters used herein include esters and carbonates formed by reacting one or more hydroxyl groups of the compound of the disclosed method with alkyl, alkoxy or aryl substituted acylating agents using procedures known to those skilled in the art to generate acetate, pivalate, methyl carbonate, benzoate, etc. As a further example, groups including but not limited to hemisuccinate, phosphate, dimethylaminoacetate and phosphoryloxymethoxycarbonyl can be used to derive free hydroxyl groups, as described in Advanced Drug Delivery Reviews, 1996, 19, 115. Also included are carbamate prodrugs of hydroxyl and amino groups, and carbonate prodrugs, sulfonate prodrugs, sulfonates and sulfates of hydroxyl groups. Free amines can also be derived into amides, sulfonamides or phosphoramides. All of the prodrug moieties described can include groups including but not limited to ethers, amines and carboxylic acid functional groups. In addition, any compound that can be converted in vivo to provide a bioactive agent (e.g., compounds of any of Formulas (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), and (1001 to 1114) is a prodrug within the scope of the present disclosure. Various forms of prodrugs are well known in the art. A comprehensive description of prodrugs and prodrug derivatives is found in: (a) The Practice of Medicinal Chemistry, Camille G. Wermuth et al., (Academic Press, 1996); (b) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985); (c) A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds., (Harwood Academic Publishers, 1991).In general, prodrugs can be designed to improve the permeability of drugs across biological membranes, thereby achieving improved drug absorption, prolonging the duration of drug action (slow release of the parent drug from the prodrug, reducing the first-pass metabolism of the drug), targeting drug action (e.g., organ or tumor targeting, lymphocyte targeting), changing or improving the aqueous solubility of drugs (e.g., intravenous formulations and eye drops), improving local drug delivery (e.g., skin and ocular drug delivery), improving the chemical / enzymatic stability of drugs or reducing off-target drug effects, and more generally to improve the therapeutic effects of the compounds used in the present disclosure.

[0093] Unless otherwise indicated, chemical structures depicted herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, one or more hydrogen atoms are replaced by deuterium or tritium, or one or more carbon atoms are enriched by 13 C or 14 Compounds having carbon substituted at least one of the carbon atoms of C are within the scope of the present disclosure.

[0094] When ranges are used herein to describe, for example, physical or chemical properties (e.g., molecular weight or chemical formula), all combinations and subcombinations of ranges and specific embodiments thereof are intended to be included. When referring to a number or a numerical range, the use of the term "about" means that the number or numerical range referred to is an approximation within the experimental variability (or within the statistical experimental error), and that the number or numerical range may vary. The variation is typically 0% to 15%, preferably 0% to 10%, and more preferably 0% to 5% of the number or numerical range. The term "comprising" (and related terms, such as "comprise" or "comprises" or "having" or "including") includes, for example, those embodiments of any material combination, method or process that is "consisting of" or "essentially consisting of" the features.

[0095] "Alkyl" refers to a group consisting of only carbon and hydrogen atoms, containing no unsaturated bonds, having 1 to 10 carbon atoms (e.g., (C 1-10 ) alkyl or C 1-10The term "alkyl" refers to a straight or branched hydrocarbon chain group of a alkyl group. Whenever it appears in this article, a numerical range such as "1 to 10" refers to each integer in a given range, for example, "1 to 10 carbon atoms" means that the alkyl group can be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, but the definition is also intended to cover the appearance of the term "alkyl" without a specific numerical range. Typical alkyl groups include but are not limited to methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl and decyl. The alkyl moiety can be connected to the rest of the molecule by a single bond, such as methyl (Me), ethyl (Et), n-propyl (Pr), 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (tert-butyl) and 3-methylhexyl. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more substituents which are independently heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR ... a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R aand R is independently hydrogen, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0096] "Alkylaryl" refers to an -(alkyl)aryl group where aryl and alkyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for aryl and alkyl respectively.

[0097] "Alkylheteroaryl" refers to an -(alkyl)heteroaryl group where heteroaryl and alkyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for aryl and alkyl respectively.

[0098] "Alkylheterocycloalkyl" or "alkylheterocyclyl" refers to an -(alkyl)heterocycloalkyl radical where alkyl and heterocycloalkyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for heterocycloalkyl and alkyl respectively.

[0099] An "alkene" moiety is a group consisting of at least two carbon atoms and at least one carbon-carbon double bond, and an "alkyne" moiety is a group consisting of at least two carbon atoms and at least one carbon-carbon triple bond. Alkyl moieties, whether saturated or unsaturated, may be branched, straight chain or cyclic.

[0100] "Alkenyl" refers to a group consisting solely of carbon and hydrogen atoms, containing at least one double bond, and having from two to ten carbon atoms (i.e., (C 2-10 ) alkenyl or C 2-10 The straight or branched hydrocarbon chain group of alkenyl) is a group of a hydrocarbon chain. Whenever it appears in this article, a numerical range such as "2 to 10" refers to each integer in a given range; for example, "2 to 10 carbon atoms" means that the alkenyl group can be composed of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. The alkenyl moiety can be connected to the rest of the molecule by a single bond, such as ethenyl (i.e., vinyl (vinyl)), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl and penta-1,4-dienyl. Unless otherwise specifically stated in this specification, alkenyl is optionally substituted with one or more substituents, and the substituents are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxyl, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(Ra )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0101] "Alkenyl-cycloalkyl" refers to an -(alkenyl)cycloalkyl radical where alkenyl and cycloalkyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for alkenyl and cycloalkyl respectively.

[0102] "Alkynyl" refers to a group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, and having from two to ten carbon atoms (i.e., (C 2-10 ) alkynyl or C 2-10 A straight or branched hydrocarbon chain group of alkynyl (alkynyl). Whenever it appears in this article, a numerical range such as "2 to 10" refers to each integer in the given range; for example, "2 to 10 carbon atoms" means that the alkynyl group can be composed of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. The alkynyl group can be connected to the rest of the molecule by a single bond (e.g., ethynyl, propynyl, butynyl, pentynyl and hexynyl). Unless otherwise specifically stated in this specification, the alkynyl group is optionally substituted with one or more substituents, which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxyl, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a 、-SR a 、-OC(O)-R a、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0103] "Alkynyl-cycloalkyl" refers to an -(alkynyl)cycloalkyl radical where alkynyl and cycloalkyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for alkenyl and cycloalkyl respectively.

[0104] "Formaldehyde" refers to a -(C=O)H group.

[0105] "Carboxy" refers to a -(C=O)OH group.

[0106] "Cyano" refers to a -CN group.

[0107] "Cycloalkyl" refers to a monocyclic or polycyclic group containing only carbon and hydrogen and may be saturated or partially unsaturated. Cycloalkyl includes groups having 3 to 10 ring atoms (i.e., (C 3-10 ) cycloalkyl or C 3-10Cycloalkyl). Whenever it appears in the present invention, a numerical range such as "3 to 10" refers to each integer in the given range; for example, "3 to 10 carbon atoms" means that the cycloalkyl group can be composed of 3 carbon atoms, etc., up to and including 10 carbon atoms. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornyl, etc. Unless otherwise specifically stated in the specification, the cycloalkyl group is optionally substituted with one or more substituents, which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0108] "Cycloalkyl-alkenyl" refers to a -(cycloalkyl)alkenyl radical where cycloalkyl and alkenyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for cycloalkyl and alkenyl respectively.

[0109] "Cycloalkyl-heterocycloalkyl" refers to a -(cycloalkyl)heterocycloalkyl radical where cycloalkyl and heterocycloalkyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for cycloalkyl and heterocycloalkyl respectively.

[0110] "Cycloalkyl-heteroaryl" refers to a -(cycloalkyl)heteroaryl radical where cycloalkyl and heteroaryl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for cycloalkyl and heteroaryl respectively.

[0111] The term "alkoxy" refers to the group -O-alkyl, including straight chain, branched, cyclic configurations and combinations thereof of 1 to 10 carbon atoms connected to the parent structure through an oxygen. Examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy and cyclohexyloxy. "Lower alkoxy" refers to an alkoxy group containing 1 to 6 carbons.

[0112] The term "substituted alkoxy" refers to an alkoxy group in which the alkyl component is substituted (i.e., -O-(substituted alkyl)). Unless otherwise specifically stated in the specification, the alkyl portion of the alkoxy group is optionally substituted with one or more substituents which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a(where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0113] The term "alkoxycarbonyl" refers to a radical of the formula (alkoxy)(C=O)- attached through the carbonyl carbon, wherein the alkoxy group has the indicated number of carbon atoms. 1-6 )Alkoxycarbonyl is an alkoxy group having 1 to 6 carbon atoms attached to a carbonyl linker via its oxygen. "Lower alkoxycarbonyl" refers to an alkoxycarbonyl group in which the alkoxy group is a lower alkoxy group.

[0114] The term "substituted alkoxycarbonyl" refers to the group (substituted alkyl)-OC(O)-, wherein the group is attached to the parent structure via the carbonyl functional group. Unless otherwise specifically stated in the specification, the alkyl portion of the alkoxycarbonyl group is optionally substituted with one or more substituents, which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) tN(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0115] The term "cycloalkyloxy" refers to a cycloalkyl group having the specified number of carbon atoms attached through an oxygen atom (eg, cyclopropyloxy and cyclohexyloxy).

[0116] "Acyl" refers to the groups (alkyl)-C(O)-, (aryl)-C(O)-, (heteroaryl)-C(O)-, (heteroalkyl)-C(O)-, and (heterocycloalkyl)-C(O)-, wherein the group is attached to the parent structure through a carbonyl functional group. If the R group is heteroaryl or heterocycloalkyl, the heterocyclic or chain atoms account for the total number of chain or ring atoms. Unless otherwise specifically stated in the specification, the alkyl, aryl or heteroaryl portion of the acyl group is optionally substituted with one or more substituents, which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (Ra )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0117] "Acyloxy" refers to a R(C=O)O- group, where R is alkyl, aryl, heteroaryl, heteroalkyl or heterocycloalkyl, as described herein. If the R group is heteroaryl or heterocycloalkyl, the heterocyclic or chain atoms account for the total number of chain or ring atoms. Unless otherwise specifically stated in the specification, the R of the acyloxy group is optionally substituted with one or more substituents, which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0118] "Acylsulfonamide" refers to -S(O)2-N(R a )-C(=O)- group, wherein Ra is hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl. Unless otherwise specifically stated in the specification, the acylsulfonamide is optionally substituted with one or more substituents, which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxyl, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a are independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl

[0119] "Alkylcycloalkyl" refers to an optionally substituted ring system comprising a cycloalkyl group having one or more alkyl substituents, wherein the cycloalkyl group and the alkyl group are each as previously defined. Exemplary alkylcycloalkyl groups include, for example, 2-methylcyclohexyl, 3,3-dimethylcyclopentyl, trans-2,3-dimethylcyclooctyl, and 4-methyldecahydronaphthyl.

[0120] "Alkylheterocyclenyl" refers to a heterocycloalkyl or heterocyclyl group as defined herein further comprising 1 or 2 double bonds and having one or more alkyl substituents.

[0121] "Amino" or "amine" refers to -N(R a )2 group, wherein each R a are independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, unless otherwise specifically stated in the specification. a )2 group has two R other than hydrogen a When substituents are present, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. a )2 is intended to include, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. Unless otherwise specifically stated in the specification, amino is optionally substituted with one or more substituents, which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxyl, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R aand R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0122] The term "substituted amino" also refers to -NHR as described above, respectively. a and NR a R a N-oxides of the groups. N-oxides can be prepared by treating the corresponding amino group with, for example, hydrogen peroxide or m-chloroperbenzoic acid.

[0123] "Amide" or "amido" refers to a chemical moiety having the formula -C(O)N(R)2 or -NHC(O)R, wherein R is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heteroalicyclic (bonded through a ring carbon), each of which itself may be optionally substituted. The R2 in the -N(R)2 of the amide may optionally form a 4, 5, 6, or 7-membered ring together with the nitrogen to which it is attached. Unless otherwise specifically stated in the specification, the amide group is optionally substituted independently by one or more substituents described herein for alkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl. Amides may be amino acids or peptide molecules attached to the compounds disclosed herein, thereby forming prodrugs. The procedures and specific groups for making such amides are known to those skilled in the art and can be easily found in classical materials, such as Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, New York, NY, 1999, which are incorporated herein by reference in their entirety.

[0124] "Aromatic" or "aryl" or "Ar" refers to an aromatic group having 6 to 10 ring atoms (e.g., C6-C 10 Aromatic or C6-C 10A divalent group formed by a substituted benzene derivative and having a free valence on a ring atom is called a substituted phenylene group. A divalent group derived from a monovalent polycyclic hydrocarbon group whose name ends with "-yl" by removing a hydrogen atom from a carbon atom with a free valence is named by adding "-subunit" to the name of the corresponding monovalent group, for example, a naphthyl group with two points of attachment is called a naphthylene group. Whenever it appears in this article, a numerical range such as "6 to 10" refers to each integer within a given range; for example, "6-10 ring atoms" means that the aryl group can be composed of 6 ring atoms, 7 ring atoms, etc., up to and including 10 ring atoms. The term includes monocyclic or fused-ring polycyclic (i.e., rings that share adjacent pairs of ring atoms) groups. Unless otherwise specifically stated in the specification, an aryl moiety is optionally substituted with one or more substituents which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -OR ... a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R aand R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0125] The term "aryloxy" refers to the group -O-aryl.

[0126] The term "substituted aryloxy" refers to an aryloxy group in which the aryl substituent is substituted (i.e., -O-(substituted aryl)). Unless otherwise specifically stated in the specification, the aryl portion of the aryloxy group is optionally substituted with one or more substituents which are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0127] "Aralkyl" or "arylalkyl" refers to an (aryl)alkyl group where aryl and alkyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for aryl and alkyl respectively.

[0128] "Cycloalkylalkyl" refers to an alkyl group in which one hydrogen atom is replaced by a cycloalkyl group. In some embodiments, the hydrogen atom on the terminal carbon atom of the alkyl group is replaced by a cycloalkyl group. In some embodiments, the cycloalkyl group is C 3-6 Cycloalkyl, in some embodiments C 5-6 In some embodiments, the alkanediyl portion of the cycloalkylalkyl group may be, for example, C 1-10 Alkanediyl, C 1-6 Alkanediyl, C 1-4 Alkanediyl, C 1-3 In some embodiments, cycloalkylalkyl is C 4-16 Cycloalkylalkyl, C 4-12 Cycloalkylalkyl, C 4-10 Cycloalkylalkyl, C 6-12 Cycloalkylalkyl or C 6-9 Cycloalkylalkyl. For example, C 6-9 The cycloalkylalkyl group includes a C3 alkyl group bonded to a cyclopentyl group or a cyclohexyl group.

[0129] "Ester" refers to a chemical group having a chemical formula of -COOR, wherein R is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded by ring carbon) and heteroalicyclic (bonded by ring carbon). The procedure and specific groups for making esters are known to those skilled in the art, and can be easily found in classical materials, such as Greene and Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York, NY, 1999, which are incorporated herein by reference in their entirety. Unless otherwise specifically stated in this specification, an ester group is optionally substituted with one or more substituents, and the substituents are independently alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxyl, halogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(Ra )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0130] "Fluoroalkyl" refers to an alkyl group as defined above substituted with one or more fluoro groups as defined above, for example, trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. The alkyl portion of the fluoroalkyl group may be optionally substituted as described above for alkyl.

[0131] "Halo", "halide" or "halogen" is intended to refer to fluorine, chlorine, bromine or iodine. The terms "haloalkyl", "haloalkenyl", "haloalkynyl" and "haloalkoxy" include alkyl, alkenyl, alkynyl and alkoxy structures substituted with one or more halogen groups or combinations thereof. For example, the terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy, respectively, wherein the halogen is fluorine.

[0132] "Heteroalkyl", "heteroalkenyl" and "heteroalkynyl" refer to optionally substituted alkyl, alkenyl and alkynyl groups having one or more backbone atoms selected from atoms other than carbon (e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof). A numerical range may be given - for example, C1-C4 heteroalkyl, which refers to the total chain length, which in this example is 4 atoms long. The heteroalkyl group may be substituted with one or more substituents, which are independently: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thio, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a)2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1or2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0133] "Heteroalkylaryl" refers to a -(heteroalkyl)aryl radical where heteroalkyl and aryl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for heteroalkyl and aryl respectively.

[0134] "Heteroalkylheteroaryl" refers to a -(heteroalkyl)heteroaryl radical where heteroalkyl and heteroaryl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for heteroalkyl and heteroaryl respectively.

[0135] "Heteroalkylheterocycloalkyl" refers to a -(heteroalkyl)heterocycloalkyl radical where heteroalkyl and heterocycloalkyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for heteroalkyl and heterocycloalkyl respectively.

[0136] "Heteroalkylcycloalkyl" refers to a -(heteroalkyl)cycloalkyl radical where heteroalkyl and cycloalkyl are as disclosed herein and which are optionally substituted by one or more of the substituents described as suitable substituents for heteroalkyl and cycloalkyl respectively.

[0137] "Heteroaryl" or "heteroaromatic" or "HetAr" or "Het" refers to a 5- to 18-membered aromatic radical (e.g., C5-C 13 The term "heteroaryl" refers to any of a number of rings, such as "heteroaryl" and "heteroaryl", and it can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system. Whenever it appears in this article, a numerical range such as "5 to 18" refers to each integer in a given range, for example, "5 to 18 ring atoms" means that the heteroaryl group can be composed of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. The divalent group derived from the monovalent heteroaryl group whose name ends with "-base" by removing a hydrogen atom from an atom with a free valence is named by adding "-subunit" in the name of the corresponding monovalent group, for example, the pyridyl with two attachment points is a pyridyl subunit. The "heteroaromatic" or "heteroaryl" part containing N refers to an aromatic group in which at least one skeleton atom of the ring is a nitrogen atom. Polycyclic heteroaryl can be fused or non-fused. One or more heteroatoms in the heteroaryl group are optionally oxidized. If present, one or more nitrogen atoms can be optionally quaternized. The heteroaryl group can be connected to the rest of the molecule by any atom of one or more rings. Examples of heteroaryl groups include, but are not limited to, aza benzo[b][1,4]dioxolyl, benzofuranyl, benzoxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxolyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyrone, benzofuranyl, benzofuranone, benzofurazanyl, benzothiazolyl, benzothiophenyl (benzothienyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6, 7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furazanyl, furanonyl, furano[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolyl, isoindolyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridonyl, oxadiazolyl, 2-oxoazepine yl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolyl, isoquinolyl, tetrahydroquinolyl, 5, 6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, thiapyranyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pyridinyl and thienyl (i.e., thienyl). Unless otherwise specifically stated in the specification, the heteroaryl moiety is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thio, trimethylsilyl, -OR a 、-SRa 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0138] Substituted heteroaryl also includes ring systems substituted with one or more oxide (-O-) substituents, for example, pyridinyl N-oxide.

[0139] "Heteroaralkyl" refers to a moiety having an aryl portion as described herein attached to an alkylene portion as described herein, wherein the attachment to the rest of the molecule is through the alkylene group.

[0140] "Heterocycloalkyl" or "heterocyclyl" refers to a stable 3- to 18-membered non-aromatic ring group containing 2 to 12 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur. Whenever it appears in this article, a numerical range such as "3 to 18" refers to each integer in a given range, for example, "3 to 18 ring atoms" means that the heterocycloalkyl can be composed of 3 ring atoms, 4 ring atoms, etc., up to and including 18 ring atoms. Unless otherwise specifically stated in this specification, the heterocycloalkyl group is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include a fused or bridged ring system. The heteroatoms in the heterocycloalkyl group may be optionally oxidized. If present, one or more nitrogen atoms may be optionally quaternized. The heterocycloalkyl group is partially or completely saturated. The heterocycloalkyl group may be connected to the rest of the molecule by any atom of one or more rings. Examples of such heterocycloalkyl groups include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless otherwise specifically stated in the specification, the heterocycloalkyl moiety is optionally substituted by one or more substituents which independently are: alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, nitro, oxo, thio, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2. -C(O)R a 、-C(O)OR a 、-OC(O)N(R a )2、-C(O)N(R a )2、-N(R a )C(O)OR a 、-N(R a )C(O)R a 、-N(R a )C(O)N(R a )2、N(R a )C(NR a )N(R a )2、-N(R a )S(O) t R a (where t is 1 or 2), -S(O)t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t N(R a )2 (where t is 1 or 2) or PO3 (R a )2, where each R a and R is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl.

[0141] "Heterocycloalkyl" also includes bicyclic ring systems in which one non-aromatic ring typically has 3 to 7 ring atoms and contains at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur and nitrogen and combinations comprising at least one of the foregoing heteroatoms; the other ring typically has 3 to 7 ring atoms, optionally contains 1-3 heteroatoms independently selected from oxygen, sulfur and nitrogen, and is not aromatic.

[0142] "Heterocycloalkenyl" refers to a heterocycloalkyl or heterocyclyl group as defined above and further includes 1 or 2 double bonds. Non-limiting examples of heterocycloalkenyl groups include -(C4-C9)heterocycloalkenyl.

[0143] "Heterocycloalkenylalkyl" refers to an alkyl group in which one hydrogen atom is replaced by a heterocycloalkenyl group. In some embodiments, the hydrogen atom on the terminal carbon atom of the alkyl group is replaced by a heterocycloalkenyl group. Non-limiting examples include dihydrofuranylmethyl (e.g., 2,5-dihydrofuran-3-ylmethyl), dihydropyranylmethyl (e.g., 5,6-dihydro-2H-pyran-ylmethyl), dihydropyrrolylmethyl (3-pyrrolin-3-ylmethyl), tetrahydropyridinylmethyl (e.g., 1,2,3,6-tetrahydropyridin-4-ylmethyl), tetrahydropyridinylethyl (e.g., 1,2,3,6-tetrahydropyridin-4-yl-2-ethyl), dihydrothienylmethyl (e.g., 2,5-dihydrothien-3-ylmethyl), dihydrothiopyranylmethyl (e.g., 5,6-dihydro-2H-thiopyran-4-ylmethyl), dehydrohomopiperidinylmethyl (e.g., 4,5-dehydrohomopiperidin-4-ylmethyl), and the like.

[0144] "Nitro" refers to a -NO2 group.

[0145] "Oxa" refers to an -O- group.

[0146] "Oxo" refers to a =0 group.

[0147] "Isomers" are different compounds with the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space - that is, they have different stereochemical configurations. "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. Where appropriate, the term "(±)" is used to represent a racemic mixture. "Diastereomers" are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other. Absolute stereochemistry is specified according to the Cahn-Ingold-Prelog RS system. When a compound is a pure enantiomer, the stereochemistry of each chiral carbon can be specified with (R) or (S). Resolved compounds whose absolute configuration is unknown can be specified as (+) or (-), depending on the direction (right-handed or left-handed) in which they rotate plane polarized light at the wavelength of the sodium D line. According to absolute stereochemistry, certain compounds described herein contain one or more asymmetric centers and can thus produce enantiomers, diastereomers, and other stereoisomeric forms that can be defined, such as (R) or (S). The chemical entities, pharmaceutical compositions and methods of the present invention are intended to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)-isomers and (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless otherwise specified, the compounds are expected to include both E and Z geometric isomers.

[0148] As used herein, "enantiomeric purity" refers to the relative amount of a particular enantiomer present relative to the amount of the other enantiomer, expressed as a percentage. For example, if a compound may have an (R)- or (S)-isomer configuration and is present as a racemic mixture, the enantiomeric purity relative to the (R)- or (S)-isomer is about 50%. If one isomeric form predominates over the other in the compound, for example 80% (S)-isomer and 20% (R)-isomer, the enantiomeric purity of the compound relative to the (S)-isomer is 80%. The enantiomeric purity of a compound can be determined by a variety of methods known in the art, including but not limited to chromatography using a chiral support, polarization measurement of polarized light rotation, nuclear magnetic resonance spectroscopy using a chiral shift reagent (including but not limited to chiral complexes containing lanthanides or Pirkle reagents), or derivatization of the compound with a chiral compound (e.g., Mosher's acid) followed by chromatography or nuclear magnetic resonance spectroscopy.

[0149] In some embodiments, the composition of enantiomer enrichment has a higher efficacy than the racemic mixture of the composition in terms of unit mass therapeutic utility. Enantiomers can be separated from the mixture by methods known to those skilled in the art (including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts); or preferred enantiomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions, Wiley Interscience, New York (1981); ELEiel, Stereochemistry of Carbon Compounds, McGraw-Hill, New York (1962); and ELEiel and SH Wilen, Stereochemistry of Organic Compounds, Wiley-Interscience, New York (1994).

[0150] As used herein, the terms "enantiomerically enriched" and "non-racemic" refer to a composition in which the weight percentage of one enantiomer is greater than the amount of that enantiomer in a control mixture of a racemic composition (e.g., a weight ratio greater than 1:1). For example, an enantiomerically enriched preparation of the (S)-enantiomer refers to a preparation of the compound in which the (S)-enantiomer is present at greater than 50% by weight, such as at least 75% by weight, or, for example, at least 80% by weight relative to the (R)-enantiomer. In some embodiments, the degree of enrichment can be significantly greater than 80% by weight, thereby providing a "substantially enantiomerically enriched" or "substantially non-racemic" preparation, which refers to a preparation of the composition in which one enantiomer is present at least 85% by weight, such as at least 90% by weight, or, for example, at least 95% by weight relative to the other enantiomer. The terms "enantiomerically pure" or "substantially enantiomerically pure" refer to a composition comprising at least 98% of a single enantiomer and less than 2% of the opposite enantiomer.

[0151] "Moiety" refers to a specific portion or functional group of a molecule. A chemical moiety is generally identified as a chemical entity embedded in or attached to a molecule.

[0152] "Tautomers" refers to structurally different isomers that interconvert via tautomerization. "Tautomerization" is a form of isomerization that includes prototropic or prototropic tautomerization and is considered a subset of acid-base chemistry. "Prototropic tautomerization" or "prototropic tautomerization" involves the migration of a proton with a change in bond order, typically the exchange of a single bond with an adjacent double bond. Where tautomerization is possible (e.g., in solution), a chemical equilibrium of tautomers can be achieved. An example of tautomerization is keto-enol tautomerization. A specific example of keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4(1H)-one tautomers.

[0153] A "leaving group or atom" is any group or atom that separates from the starting material under the selected reaction conditions to promote the reaction at a specified site. Unless otherwise specified, examples of such groups include halogen atoms and methanesulfonyloxy, p-nitrobenzenesulfonyloxy and toluenesulfonyloxy groups.

[0154] "Protecting group" is intended to refer to a group that selectively blocks one or more reactive sites in a multifunctional compound, so that a chemical reaction can be selectively carried out on another unprotected reactive site, and the group can be easily removed or deprotected after the selective reaction is completed. For example, various protecting groups are disclosed in TH Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, New York (1999).

[0155] "Solvate" refers to a compound that is physically associated with one or more pharmaceutically acceptable solvent molecules.

[0156] "Substituted" means that the group mentioned may have attached one or more additional groups, radicals or moieties, which are independently selected from, for example, acyl, alkyl, alkaryl, cycloalkyl, aralkyl, aryl, carbohydrate, carbonate, heteroaryl, heterocycloalkyl, hydroxy, alkoxy, aryloxy, thiol, alkylthio, arylthio, cyano, halo, carbonyl, ester, thiocarbonyl, isocyanato, thiocyanato, isothiocyanato, nitro, oxo, perhaloalkyl, perfluoroalkyl, phosphate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea and amino, including mono- and di-substituted amino, and protected derivatives thereof. The substituents themselves may be substituted, for example, a cycloalkyl substituent itself may have a halide substituent on one or more of its ring carbons. The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.

[0157] "Sulfanyl" refers to groups including -S-(optionally substituted alkyl), -S-(optionally substituted aryl), -S-(optionally substituted heteroaryl), and -S-(optionally substituted heterocycloalkyl).

[0158] "Sulfinyl" refers to groups including -S(O)-H, -S(O)-(optionally substituted alkyl), -S(O)-(optionally substituted amino), -S(O)-(optionally substituted aryl), -S(O)-(optionally substituted heteroaryl), and -S(O)-(optionally substituted heterocycloalkyl).

[0159] "Sulfonyl" refers to groups including -S(O2)-H, -S(O2)-(optionally substituted alkyl), -S(O2)-(optionally substituted amino), -S(O2)-(optionally substituted aryl), -S(O2)-(optionally substituted heteroaryl) and -S(O2)-(optionally substituted heterocycloalkyl).

[0160] "Sulfonamidyl" or "sulfonamido" refers to a -S(=O)2-NRR group, wherein each R is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heteroalicyclic (bonded through a ring carbon). The R group in the -NRR of the -S(=O)2-NRR group can form a 4-, 5-, 6-, or 7-membered ring together with the nitrogen to which it is attached. The sulfonamido group is optionally substituted with one or more substituents described for alkyl, cycloalkyl, aryl, and heteroaryl, respectively.

[0161] "Sulfonyloxy" refers to a -S(=O)2OH group.

[0162] "Sulfonate" refers to a -S(=O)2-OR group, where R is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heteroalicyclic (bonded through a ring carbon). The sulfonate group is optionally substituted on R with one or more substituents described for alkyl, cycloalkyl, aryl, heteroaryl, respectively.

[0163] Compounds of the present disclosure also include crystalline forms and amorphous forms of these compounds, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, non-solvated polymorphs (including anhydrates), conformational polymorphs and amorphous forms of the compounds, and mixtures thereof. "Crystalline form" and "polymorph" are intended to include all crystalline forms and amorphous forms of the compounds, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, non-solvated polymorphs (including anhydrates), conformational polymorphs and amorphous forms, and mixtures thereof, unless a specific crystalline form or amorphous form is mentioned.

[0164] For the avoidance of doubt, it is intended that a particular feature (e.g., integer, property, value, use, disease, formula, compound or group) described in conjunction with a particular aspect, embodiment or example of the present disclosure be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. Such features may therefore be used in conjunction with any definition, claim or embodiment defined herein, where appropriate. All features disclosed in this specification (including any accompanying claims, abstract and drawings) and / or all steps of any method or process so disclosed may be combined in any combination, except combinations where at least some of the features and / or steps are mutually exclusive. The present disclosure is not limited to any details of any disclosed embodiment. The present disclosure extends to any novel feature or novel combination of features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel feature or novel combination in the steps of any method or process so disclosed.

[0165] In addition, the term "about" as used herein means that dimensions, sizes, formulations, parameters, shapes, and other quantities and characteristics are not and need not be exact, but can be approximate and / or larger or smaller as desired, reflecting tolerances, conversion factors, rounding, measurement errors, etc., and other factors known to those skilled in the art. In general, dimensions, sizes, formulations, parameters, shapes, or other quantities or characteristics are "about" or "approximate", whether or not explicitly stated. It should be noted that embodiments of significantly different sizes, shapes, and dimensions can employ the described arrangements.

[0166] In addition, the transition terms "comprising," "consisting essentially of," and "consisting of," when used in the appended claims in their original and amended forms, define the claim scope, wherein other claim elements or steps, if any, that are not recited are excluded from the claim scope. The term "comprising" is intended to be inclusive or open-ended and does not exclude any other, unrecited elements, methods, steps, or materials. The term "consisting of" excludes any elements, steps, or materials other than those specified in the claim and, in the latter case, excludes impurities that are normally associated with the specified materials. The term "consisting essentially of" limits the scope of the claim to the specified elements, steps, or materials and those that do not materially affect the basic and novel features of the present disclosure. Alternatively, all embodiments of the present disclosure may be more specifically defined by any of the transition terms "comprising," "consisting essentially of," and "consisting of."

[0167] AMPK modulators

[0168] In one aspect, the present disclosure provides novel compounds that modulate AMPK. In some embodiments, the compounds of the present disclosure are AMPK agonists. In some embodiments, the compounds of the present disclosure are AMPK inhibitors.

[0169] In one aspect, the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

[0170]

[0171] Wherein in formula (I):

[0172] X1 for CR 4a or N;

[0173] X2 for CR 4b or N;

[0174] R1 is selected from

[0175] R2 is H, -CF3 or halogen;

[0176] R3 at each occurrence is independently selected from halo, -CN, -N(R 10 2. C 1-10 Alkyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkyloxy, C 3-10 Heterocyclic group, C 4-12Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 Heterocycloalkenylalkyl, aryl and heteroaryl, wherein C 1-10 Alkyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 The heterocycloalkenyl alkyl, aryl or heteroaryl groups are unsubstituted or substituted with one to three radicals selected from deuterium, halo, C 1-6 Alkyl, C 3-6 Substitution by substituents of cycloalkyl, -OR5 and -OCOR7;

[0177] R 4a is independently selected at each occurrence from H, halo, C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl and C 4-10 Cycloalkylalkyl, wherein C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl or C 4-10 Cycloalkylalkyl is unsubstituted or substituted with one to three halogen substituents;

[0178] R 4b independently selected at each occurrence from H, C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl and C 4-10 Cycloalkylalkyl, wherein C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl or C 4-10 Cycloalkylalkyl is unsubstituted or substituted with one to three halogen substituents;

[0179] R5 at each occurrence is independently selected from H, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl and C4-10 Cycloalkylalkyl, wherein C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl or C 4-10 Cycloalkylalkyl is unsubstituted or substituted with one to three halogen substituents;

[0180] R6 at each occurrence is independently selected from H, C 1-6 Alkyl and C 3-6 Cycloalkyl;

[0181] R7 is independently selected at each occurrence from C 1-10 Alkyl, C 3-7 Cycloalkyl and C 4-12 Alkylcycloalkyl, wherein C 1-10 Alkyl, C 3-7 Cycloalkyl or C 4-12 Alkylcycloalkyl is unsubstituted or substituted by one to three groups selected from halogen, C 1-10 Alkyl and -NR 12 , R 12 Substituents are substituted;

[0182] R8 is selected from H, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-10 Heterocyclic group, C 4-12 Alkyl heterocyclic group, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 Heterocycloalkenylalkyl, aryl, heteroaryl, Among them C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-10 Heterocyclic group, C 4-12 Alkyl heterocyclic group, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 Heterocycloalkenylalkyl, aryl or heteroaryl is unsubstituted or substituted with one to three substituents selected from deuterium, halo and -OR5;

[0183] R 10 independently selected at each occurrence from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 4-12Alkylcycloalkyl, and C 3-10 Heterocyclic group, wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, C 4-12 Alkylcycloalkyl or C 3-10 The heterocyclic group is unsubstituted or substituted by one to three radicals selected from deuterium, halogen, C 1-6 Alkyl and C 3-6 Substitution of cycloalkyl groups;

[0184] R 11 In each occurrence, independently selected from -OR 12 and -N(R 12 )2;

[0185] R 12 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-10 Haloalkoxy and C 3-6 Cycloalkyl;

[0186] n is an integer from 0 to 3;

[0187] p is an integer from 1 to 5;

[0188] q is an integer from 0 to 5;

[0189] r is an integer from 1 to 5;

[0190] s is an integer from 1 to 5;

[0191] A is selected from phenyl, pyridyl, pyrimidinyl, pyridazinyl and the following 5-membered heterocyclic rings:

[0192]

[0193] The premise is that the compound of formula (I) is not

[0194] In some embodiments, X1 is CR 4a In some embodiments, R 4a is H, Cl or F.

[0195] In some embodiments, X2 is CR 4b In some embodiments, X2 is N or CR 4b , where R 4b is H. In some embodiments, R 4b C 1-10 In one embodiment, R 4b For CH3.

[0196] In one embodiment, A is selected from phenyl, pyridinyl, pyrimidinyl, pyridazinyl and the following 5-membered heterocyclic rings:

[0197]

[0198] In some embodiments, A and / or the 5-membered heterocyclic ring is selected from

[0199]

[0200] In some embodiments, A is selected from:

[0201] In one embodiment, R2 is halo. In one embodiment, R2 is Cl or F.

[0202] In one embodiment, R6 is H.

[0203] In one aspect, the present disclosure provides a compound of formula (10), (11), (12), (13), (14), (15), (16), or (17), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0204]

[0205] In some embodiments, R1 is

[0206] In one aspect, the present disclosure provides a compound of Formula (100), Formula (110), Formula (120), Formula (130), Formula (140), Formula (150), Formula (160), or Formula (170), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0207]

[0208] In some embodiments, R1 is

[0209] In one embodiment, the compound of formula (I) is a compound of formula (200), formula (210), formula (220), formula (230), formula (240), formula (250), formula (260), or formula (270), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0210]

[0211] In one embodiment, R1 is

[0212] In one embodiment, the compound of formula (I) is a compound of formula (300), formula (310), formula (320), formula (330), formula (340), formula (350), formula (360), or formula (370), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0213]

[0214] In one embodiment, the compound of any one of formulae (300)-(370) is selected from:

[0215]

[0216]

[0217] In one embodiment, R1 is

[0218] In one embodiment, the compound of formula (I) is a compound of formula (400), formula (410), formula (420), formula (430), formula (440), formula (450), formula (460), or formula (470), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0219]

[0220] In one embodiment, R1 is

[0221] In one embodiment, the compound of formula (I) is a compound of formula (500), formula (510), formula (520), formula (530), formula (540), formula (550), formula (560), or formula (570), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0222]

[0223] In one embodiment, R1 is

[0224] In one embodiment, the compound of formula (I) is a compound of formula (600), formula (610), formula (620), formula (630), formula (640), formula (650), formula (660), or formula (670), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0225]

[0226] In one embodiment, R1 is

[0227] In one embodiment, the compound of formula (I) is a compound of formula (700), formula (710), formula (720), formula (730), formula (740), formula (750), formula (760), or formula (770), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0228]

[0229] In one embodiment, R1 is

[0230] In one embodiment, the compound of formula (I) is a compound of formula (800), formula (810), formula (820), formula (830), formula (840), formula (850), formula (860), or formula (870), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0231]

[0232] In one embodiment, R1 is

[0233] In one embodiment, the compound of formula (I) is a compound of formula (900), formula (910), formula (920), formula (930), formula (940), formula (950), formula (960), or formula (970), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0234]

[0235] In some embodiments, R 10 Selected from H, methyl, ethyl, -CD3, n-butyl,

[0236] In some embodiments, R 11 Selected from

[0237] In some embodiments, p is 2 or 3.

[0238] In some embodiments, R3 is selected from -F, -CN, ethyl, Optionally

[0239] In some embodiments, R3 is selected from

[0240] Optionally selected from In some embodiments, for In some embodiments, for

[0241] In some embodiments, q is 0 or 1.

[0242] In some embodiments, r is 2 or 3.

[0243] In some embodiments, s is 1.

[0244] In some embodiments, R 12 Selected from methyl, ethyl, -OCF3 and In some embodiments, R8 comprises one or more -OCF3 groups. In some embodiments, R8 is selected from H and methyl.

[0245] In some embodiments, R8 is selected from H, methyl, ethyl, isopropyl, n-butyl, tert-butyl,

[0246] In one embodiment, R8 is selected from H, methyl and ethyl.

[0247] In some embodiments, in Formula (10), Formula (100), Formula (200), Formula (300), Formula (500), Formula (600), Formula (700), or Formula (800), R3 is selected from C 1-10 Alkyl, C 1-10 Alkoxy, -CF3, -OCF3, In one embodiment, in formula (100), R3 is selected from C 1-10 Alkyl, C 1-10 Alkoxy, -CF3, -OCF3, In one embodiment, in formula (200), R3 is C 1-10 In one embodiment, in formula (300), R3 is C 1-10 In one embodiment, in formula (500), R3 is C 1-10 In one embodiment, in formula (600), R3 is C 1-10 In one embodiment, in formula (700), R3 is C 1-10 In one embodiment, in formula (800), R3 is C 1-10 In one embodiment, in formula (900), R3 is C 1-10 Alkoxy.

[0248] In some embodiments, in Formula (11), Formula (110), Formula (710) or Formula (810), R3 is selected from Optionally selected from In one embodiment, in formula (110), R3 is selected from Optionally selected from In one embodiment, in formula (710), R3 is selected from Optionally selected from In one embodiment, in formula (810), R3 is

[0249] In some embodiments, in Formula (12), Formula (130), Formula (230) or Formula (330), R3 is Optionally

[0250] In some embodiments, in Formula (13), Formula (120) or Formula (420), R3 is

[0251] In some embodiments, in formula (14) or formula (140), each R3 is independently selected from -F and -OCH3, and each R 10 Independently for C 1-10 In one embodiment, in formula (140), one R3 is -F, one R3 is -OCH3, and each R 10 It is -CH3.

[0252] In some embodiments, in formula (15), formula (150) or formula (350), each R3 is independently selected from -OCH3, -CN, -N(CH3)2, -Cl and ethyl. In one embodiment, in formula (150), one R3 is -N(CH3)2 and one R3 is selected from -OCH3, -Cl and ethyl. In another embodiment, in formula (150), one R3 is -CN and one R3 is -OCH3. In one embodiment, in formula (350), one R3 is -N(CH3)2 and one R3 is -OCH3.

[0253] In some embodiments, in formula (16) or formula (160), R3 is selected from

[0254] In some embodiments, in formula (17) or formula (170), R3 is selected from

[0255] In one embodiment, X1 is N, and the compound of formula (I) is a compound of formula (20), formula (21), formula (22), formula (23), formula (24), formula (25), or formula (26), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof:

[0256]

[0257] wherein R2 is selected from H and -Cl, and each R 4b Independently selected from H and C 1-10 alkyl.

[0258] In one embodiment, the present disclosure provides a compound of formula (20), wherein R1 is And R 4b is H. In one embodiment, the present disclosure provides a compound of formula (20), wherein R1 is And R8 is C 1-10 In one embodiment, the present disclosure provides a compound of formula (20), wherein R1 is R3 is C 1-10 alkoxy, and each R 10 Independently for C 1-10 In one embodiment, the present disclosure provides a compound of formula (20), wherein R1 is R 4b is H, R3 is C 1-10 Alkoxy, R8 is C 1-10 alkyl, and each R 10 Independently for C 1-10 In one embodiment, the present disclosure provides a compound of formula (20), wherein R1 is R 4b is H, R3 is -OCH3, R8 is selected from methyl and ethyl, and each R 10 are independently methyl.

[0259] In one embodiment, the present disclosure provides a compound of formula (21), wherein R1 is And R 4b is H. In one embodiment, the present disclosure provides a compound of formula (21), wherein R1 is and R2 is H. In one embodiment, the present disclosure provides a compound of formula (21), wherein R1 is And R3 is (Optionally In one embodiment, the present disclosure provides a compound of formula (21), wherein R1 is Where R8 is C 1-10In one embodiment, the present disclosure provides a compound of formula (21), wherein R1 is R2 is H, R3 is (Optionally ), R 4b is H, and R8 is methyl.

[0260] In one embodiment, A is R1 is And the compound of formula (I) is a compound of formula (180):

[0261]

[0262] In one embodiment, the compound of formula (I) is a compound of formula (180), wherein R8 is C 1-10 In one embodiment, the compound of formula (I) is a compound of formula (180), wherein R3 is C 1-10 alkoxy, and each R 10 Independently for C 1-10 In one embodiment, the compound of formula (I) is a compound of formula (180), wherein R3 is -OCH3, R8 is methyl, and each R 10 It is methyl.

[0263] In one embodiment, A is R1 is And the compound of formula (I) is a compound of formula (190):

[0264]

[0265] In one embodiment, the compound of formula (I) is a compound of formula (190), wherein R8 is C 1-10 In one embodiment, the compound of formula (I) is a compound of formula (190), wherein R3 is C 1-10 alkoxy, and each R 10 Independently for C 1-10 In one embodiment, the compound of formula (I) is a compound of formula (190), wherein R3 is -OCH3, R8 is methyl, and each R 10 It is methyl.

[0266] In some embodiments, the compound of Formula (I) is selected from a compound having a formula selected from Formula 1001-1114, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

[0267]

[0268]

[0269]

[0270]

[0271]

[0272]

[0273]

[0274]

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283] or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof. In some embodiments, the compound of formula (I) is selected from:

[0284]

[0285] In some embodiments, the compound of formula (I) is selected from:

[0286]

[0287]

[0288]

[0289] In some embodiments, the compound of formula (I) is selected from:

[0290]

[0291]

[0292] or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof.

[0293] In some embodiments, the present disclosure provides a compound having any one of formula (I), formula (10), formula (11), formula (12), formula (13), formula (14), formula (15), formula (16), formula (17), formula (100), formula (110), formula (120), formula (130), formula (140), formula (150), formula (160), formula (170), and formulas 1001 to 1114, but excluding

[0294] In some embodiments, the present disclosure provides compounds of formula (I), wherein when A is a 5-membered heterocyclic ring and R1 is , then R8 is not H.

[0295] Treatment

[0296] The compounds and compositions described herein can be used in methods of treating diseases, conditions, disorders and / or disorders, including but not limited to: a method of treating a disorder by activating AMPK activity in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound having Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (501), Formula (502) to (503), Formula (504) to (505), Formula (506) to (507), Formula (508) to (509), Formula (510) to (511), Formula (512) to (513), Formula (514) to (515), Formula (516) to (517), Formula (518) to (519), Formula (520) to (521), Formula (521) to (522), Formula (523) to (524), Formula (525) to (526), ​​Formula (527) to (528), Formula (529) to (530), Formula (531) to (532), Formula (533) to (534), Formula (535) to (536), Formula (537) to (538), Formula (539) to (540), Formula (541) to (542), Formula (543) to (544), Formula (545) to (546), Formula (550) to (551) 70), any one of formula (600) to (670), formula (700) to (770), formula (800) to (870), formula (900) to (970), formula 1001 to 1114, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof; a method for treating a patient suffering from a mitochondrial disorder and / or dysfunction, the method comprising a therapeutically effective amount of formula (I), formula (10) to (17), formula (20) to (26), formula (100) to (190), formula (200) to (270), A compound of any one of Formulas (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), or (1001 to 1114, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof; and a method of treating a patient suffering from a mitochondrial disorder and / or dysfunction, the method comprising identifying a mitochondrial dysfunction in the individual and administering a compound having Formula ( I), a compound of any of formulas (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), or (1001 to 1114, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof.

[0297] The compounds and compositions described herein can be used in methods for treating diseases, conditions, disorders and / or dysfunctions, including but not limited to: methods for treating diseases or conditions associated with AMPK activity in a patient, the methods comprising modulating AMPK activity in the patient; and methods for treating mitochondrial disorders and / or dysfunctions, the methods comprising identifying mitochondrial disorders and / or dysfunctions in a patient, and modulating AMPK activity in the patient. In some embodiments, modulating AMPK activity comprises administering to a patient a therapeutically effective amount of a compound having any of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), (1001 to 1114), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof. In some embodiments, the disease or condition associated with AMPK activity is a mitochondrial disorder and / or dysfunction. In some embodiments, the modulating step comprises activating AMPK in the patient. In some embodiments, the activating step comprises phosphorylating AMPK or providing an agonist to AMPK. In some embodiments, the step of regulating comprises inhibiting AMPK in the subject. In some embodiments, the mitochondrial disorder and / or dysfunction is a primary mitochondrial disorder and / or dysfunction. In some embodiments, the mitochondrial disorder and / or dysfunction is a secondary mitochondrial disorder and / or dysfunction. In some embodiments, the method further comprises evaluating the efficacy of the compound in the individual.

[0298] In some embodiments, the mitochondrial disorder and / or dysfunction is a primary mitochondrial disorder and / or dysfunction. Non-limiting examples of primary mitochondrial dysfunction include autosomal dominant optic atrophy (ADOA), Alpers-Huttenlocher syndrome (nDNA defect), ataxic neuropathy syndrome (nDNA defect), Barth syndrome / lethal infantile cardiomyopathy (LIC), coenzyme Q deficiency, complex I, complex II, complex III, complex IV and complex V deficiency (single deficiency or any combination of deficiency), chronic progressive external ophthalmoplegia (CPEO), diabetes and deafness, Kearns-Sayre syndrome (mtDNA defect), leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate (LBSL-leukodystrophy), Leigh syndrome (mtDNA and nDNA defects), Leber hereditary optic neuropathy (LHON), Lufkin ... t disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke syndrome (MELAS) (mtDNA defect), mitochondrial enoyl-CoA reductase protein-associated neurodegeneration (MEPAN), myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial recessive ataxia syndrome (MIRAS), mtDNA deletion syndrome, mtDNA depletion syndrome, mtDNA maintenance disorder, mtDNA / RNA translation defect, mitochondrial tRNA synthetase defect, mitochondrial myopathy, mitochondrial neurogastroenteric encephalopathy syndrome (MNGIE), neurogenic myasthenia, ataxia, and retinitis pigmentosa (NARP), Pearson syndrome, pyruvate dehydrogenase complex deficiency (PDCD / PDH), DNA polymerase gamma deficiency (POLG), pyruvate carboxylase deficiency, and thymidine kinase 2 deficiency (TK2).

[0299] In some embodiments, the mitochondrial disorder and / or dysfunction is a secondary mitochondrial disorder and / or dysfunction. Non-limiting examples of secondary mitochondrial dysfunction include age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and other dementias, Friedreich's ataxia (FA), Huntington's disease (HD), motor neuron disease (MND), N-glycanase deficiency (NGLY1), organic acidemias, Parkinson's disease (PD) and PD-related disorders, prion diseases, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA), Becker muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, Emery-D Reifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, Charcot-Marie-Tooth disease, congenital myopathies, distal myopathies, endocrine myopathies (hyperthyroid myopathy, hypothyroid myopathy), giant axonal neuropathy, hereditary spastic paraplegia, inflammatory myopathies (dermatomyositis, inclusion body myositis, polymyositis), metabolic myopathies, neuromuscular junction disorders, autism, cancer, diabetes, metabolic syndrome, chronic fatigue syndrome, inflammatory disorders, arthritis, aging, and mitochondrial epilepsy (epilepsy secondary to primary mitochondrial disease).

[0300] In some embodiments, the compounds and compositions described herein are useful in methods of treating a disease, disorder, condition, and / or dysfunction selected from the group consisting of: treating N-glycanase (NGLY1) deficiency, age-related macular degeneration (AMD), ischemic stroke, muscular dystrophy (e.g., Duchenne muscular dystrophy and Becker muscular dystrophy), Friedreich's ataxia (FA), autoimmune disorders involving muscle (e.g., inclusion body myositis, polymyositis, and dermatomyositis), and / or neurodegenerative disorders (e.g., amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease), diabetes, metabolic disorders, and / or obesity. In other embodiments, mitochondrial dysfunction will be identified based on the molecular signature of the disease or dysfunction, such that Western blot (Western blot), polymerase chain reaction (PCR), genotyping using genetic markers (e.g., single nucleotide polymorphisms (SNPs), expressed sequence tags (ESTs), simple sequence repeats (SSRs), etc.) will identify a specific disease or dysfunction present in an individual. In some embodiments, AMPK activation in cardiac tissue can lead to reversible cardiac hypertrophy, and thus in some embodiments, the compounds and compositions described herein can be used in methods of treating diseases, disorders, conditions, and / or dysfunctions associated with dilated cardiomyopathy. (See, e.g., Arad et al., Circ Res. 2007 Mar 2; 100(4):474-88; Myers et al., Science. 2017 Aug 4; 357(6350):507-511; the disclosures of which are incorporated herein by reference in their entireties).

[0301] In some embodiments, the compounds and compositions described herein are useful in methods of treating diseases, conditions, disorders, and / or disorders including, but not limited to, ophthalmic diseases associated with mitochondrial dysfunction.

[0302] In some embodiments, the compounds and compositions described herein provide neuroprotection in individuals with ischemic stroke, improve athletic performance in individuals with mitochondrial dysfunction and muscle wasting disorders (e.g., muscular dystrophy and autoimmune myositis disorders), enhance strength, endurance, and overall motor function in muscle degenerative disorders associated with mitochondrial dysfunction, increase mitochondrial function and / or glycogen storage in skeletal muscle, normalize energy levels within skeletal muscle, thereby preventing degeneration and weakness, and / or activate AMPK in skeletal muscle.

[0303] In some embodiments, a compound having any of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), or (1001 to 1114, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or prodrug thereof, is administered in a pharmaceutical formulation. In some embodiments, the pharmaceutical formulation comprises the compound and at least one selected from a binder, a lubricant, a buffer, and a coating. In some embodiments, the compound and / or pharmaceutical formulation is administered orally. In some embodiments, the compound and / or pharmaceutical formulation is administered daily for at least one week. In some embodiments, the compound and / or pharmaceutical formulation is administered orally, subcutaneously, intravenously, intraperitoneally, intranasally, dermally, by intravitreal injection, or by inhalation.

[0304] Various animal models known in the art can be used to test the efficacy of the methods, compounds and compound combinations described herein in the treatment, prevention and / or control of the disease or illness. For example, the method for determining the efficacy of the disclosed compounds includes but is not limited to measuring pACC in a sample as an indicator of increased AMPK activity. In some embodiments, the method for assessing disease or disease symptoms includes but is not limited to viewing molecular spectra, such as genotyping, gene expression and other methods that will be understood by those of ordinary skill in the art. In some embodiments, diseases and illnesses are identified based on the symptoms exhibited by an individual. In some embodiments, diseases and illnesses are identified based on non-limiting methods, including molecular features of diseases or dysfunctions, such as Western blots (Western blots), polymerase chain reactions (PCR), genotyping using genetic markers (e.g., single nucleotide polymorphisms (SNPs), expressed sequence tags (ESTs), simple sequence repeats (SSRs), etc.).

[0305] Pharmaceutical composition

[0306] In one embodiment, the present disclosure provides pharmaceutical compositions described herein for use in treating diseases and disorders.

[0307] The pharmaceutical composition is generally formulated to provide a therapeutically effective amount of a compound of any one of Formula (I), Formulas (10) to (17), Formulas (20) to (26), Formulas (100) to (190), Formulas (200) to (270), Formulas (300) to (370), Formulas (400) to (470), Formulas (500) to (570), Formulas (600) to (670), Formulas (700) to (770), Formulas (800) to (870), Formulas (900) to (970), Formulas 1001 to 1114 as described herein, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof as an active ingredient. Generally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, carriers (including inert solid diluents and fillers), diluents (including sterile aqueous solutions and various organic solvents), penetration enhancers, solubilizers and adjuvants.

[0308] The above pharmaceutical composition is used for treating but not limited to mitochondrial dysfunction, and the pharmaceutical composition comprises one or more compounds having any one of formula (I), formula (10) to (17), formula (20) to (26), formula (100) to (190), formula (200) to (270), formula (300) to (370), formula (400) to (470), formula (500) to (570), formula (600) to (670), formula (700) to (770), formula (800) to (870), formula (900) to (970), formula 1001 to 1114, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof, and a pharmaceutically acceptable carrier. In some embodiments, the mitochondrial dysfunction is primary mitochondrial dysfunction. In some embodiments, the present invention is selected from the group consisting of autosomal dominant optic atrophy (ADOA), Alpers-Huttenlocher syndrome (nDNA defect), ataxia neuropathy syndrome (nDNA defect), Barth syndrome / lethal infantile cardiomyopathy (LIC), coenzyme Q deficiency, complex I, complex II, complex III, complex IV and complex V deficiency (single deficiency or any combination of deficiency), chronic progressive external ophthalmoplegia (CPEO), diabetes and deafness, Kearns-Sayre syndrome (mtDNA defect), leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate (LBSL-leukodystrophy), Leigh syndrome (mtDNA and nDNA defects), Leber hereditary optic neuropathy (LHON), Luf t disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke syndrome (MELAS) (mtDNA defect), mitochondrial enoyl-CoA reductase protein-associated neurodegeneration (MEPAN), myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial recessive ataxia syndrome (MIRAS), mtDNA deletion syndrome, mtDNA depletion syndrome, mtDNA maintenance disorder, mtDNA / RNA translation defect, mitochondrial tRNA synthetase defect, mitochondrial myopathy, mitochondrial neurogastroenteric encephalopathy syndrome (MNGIE), neurogenic myasthenia, ataxia and retinitis pigmentosa (NARP), Pearson syndrome, pyruvate dehydrogenase complex deficiency (PDCD / PDH), DNA polymerase gamma deficiency (POLG), pyruvate carboxylase deficiency and thymidine kinase 2 deficiency (TK2). In some embodiments, the mitochondrial dysfunction is secondary mitochondrial dysfunction.In some embodiments, the secondary mitochondrial dysfunction is selected from the group consisting of: age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and other dementias, Friedreich's ataxia (FA), Huntington's disease (HD), motor neuron disease (MND), N-glycanase deficiency (NGLY1), organic acidemias, Parkinson's disease (PD) and PD-related disorders, prion diseases, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA), Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, Em ery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, Charcot-Marie-Tooth disease, congenital myopathies, distal myopathies, endocrine myopathies (hyperthyroid myopathy, hypothyroid myopathy), giant axonal neuropathy, hereditary spastic paraplegia, inflammatory myopathies (dermatomyositis, inclusion body myositis, polymyositis), metabolic myopathies, neuromuscular junction disorders, autism, cancer, diabetes, metabolic syndrome, chronic fatigue syndrome, inflammatory disorders, arthritis, aging, and mitochondrial epilepsy (epilepsy secondary to primary mitochondrial disease).

[0309] In some embodiments, the concentration of the compound of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula (1001) to 1114, or a pharmaceutically acceptable salt thereof, provided in the pharmaceutical composition of the present disclosure is less than, for example, 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 16% or more of the pharmaceutical composition. 3%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008 %, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002% or 0.0001% w / w, w / v or v / v.

[0310] In some embodiments, the concentration of the compound of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114, or a pharmaceutically acceptable salt thereof, provided in the pharmaceutical composition of the present disclosure is independently greater than 90%, 80%, 70%, 60%, 50%, or more of the pharmaceutical composition. , 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25%, 18%, 17.75%, 17.50%, 17.25%, 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25%, 15%, 14.75%, 14.50%, 14.25%, 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50 %, 11.25%, 11%, 10.75%, 10.50%, 10.25%, 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25%, 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 125%, 1% , 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002% or 0.0001% w / w, w / v or v / v.

[0311] In some embodiments, the concentration of the compound of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114, or a pharmaceutically acceptable salt thereof, provided in the pharmaceutical composition of the present disclosure is about 0.0001% to about 50%, about 0.001% to about 40%, about In some embodiments, the present invention relates to an agent that is present in an amount within the range of 0.01% to about 30%, about 0.02% to about 29%, about 0.03% to about 28%, about 0.04% to about 27%, about 0.05% to about 26%, about 0.06% to about 25%, about 0.07% to about 24%, about 0.08% to about 23%, about 0.09% to about 22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about 18%, about 0.5% to about 17%, about 0.6% to about 16%, about 0.7% to about 15%, about 0.8% to about 14%, about 0.9% to about 12%, or about 1% to about 10% w / w, w / v or v / v.

[0312] In some embodiments, the pharmaceutical compositions of the present disclosure include those of formula (I), formula (10) to (17), formula (20) to (26), formula (100) to (190), formula (200) to (270), formula (300) to (370), formula (400) to (470), formula (500) to (570), formula (600) to (670), formula (700) to (770), formula (800) to (870), formula (900) to (970), formula (1001 to 1101) The concentration of the compound of 14 or a pharmaceutically acceptable salt thereof is in the range of about 0.001% to about 10%, about 0.01% to about 5%, about 0.02% to about 4.5%, about 0.03% to about 4%, about 0.04% to about 3.5%, about 0.05% to about 3%, about 0.06% to about 2.5%, about 0.07% to about 2%, about 0.08% to about 1.5%, about 0.09% to about 1%, about 0.1% to about 0.9% w / w, w / v or v / v of the pharmaceutical composition.

[0313] In some embodiments, the pharmaceutical compositions of the present disclosure are provided in formula (I), formula (10) to (17), formula (20) to (26), formula (100) to (190), formula (200) to (270), formula (300) to (370), formula (400) to (470), formula (500) to (570), formula (600) to (670), formula (700) to (770), formula (800) to (801), formula (802) to (803), formula (804) to (805), formula (806) to (807), formula (808) to (809), formula (900) to (910), formula (911) to (912), formula (913) to (914), formula (915) to (916) 0) to (870), the compound of formula (900) to (970), formula 1001 to 1114 or a pharmaceutically acceptable salt thereof is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95g, 0.9g, 0.85g, 0.8g, 0.75g, 0.7g, 0.65g, 0.6g, 0.55g, 0.5g, 0.45g, 0.4g, 0.35 g, 0.3g, 0.25g, 0.2g, 0.15g, 0.1g, 0.09g, 0.08g, 0.07g, 0.06g, 0.05g, 0.04g, 0.03g, 0. 0.02g, 0.01g, 0.009g, 0.008g, 0.007g, 0.006g, 0.005g, 0.004g, 0.003g, 0.002g, 0.001g, 0.0009g, 0.0008g, 0.0007g, 0.0006g, 0.0005g, 0.0004g, 0.0003g, 0.0002g or 0.0001g.

[0314] In some embodiments, the pharmaceutical compositions of the present disclosure include those of formula (I), formula (10) to (17), formula (20) to (26), formula (100) to (190), formula (200) to (270), formula (300) to (370), formula (400) to (470), formula (500) to (570), formula (600) to (670), formula (700) to (770), formula (800) to (870), formula (900) to (970), and formula (1001 to 1001). The amount of the compound of 114 or a pharmaceutically acceptable salt thereof is greater than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065g, 0.007g, 0.0075g, 0.008g, 0.0085g, 0.009g, 0.0095g, 0.01g, 0.015g, 0.02g, 0.025g, 0.03g ,0.035g,0.04g,0.045g,0.05g,0.055g,0.06g,0.065g,0.07g,0.075g,0.08g,0.085g,0.09g,0.095g,0 .1g, 0.15g, 0.2g, 0.25g, 0.3g, 0.35g, 0.4g, 0.45g, 0.5g, 0.55g, 0.6g, 0.65g, 0.7g, 0.75g, 0.8g, 0.85g , 0.9g, 0.95g, 1g, 1.5g, 2g, 2.5g, 3g, 3.5, 4g, 4.5g, 5g, 5.5g, 6g, 6.5g, 7g, 7.5g, 8g, 8.5g, 9g, 9.5g or 10g.

[0315] Each compound provided according to the present disclosure is effective over a wide dosage range. For example, in the treatment of adults, examples of dosages that can be used are independently 0.01 to 1000 mg, 0.5 to 100 mg, 1 to 50 mg / day, and 5 to 40 mg / day. The exact dosage depends on the route of administration, the form of the compound, the sex and age of the subject to be treated, the weight of the subject to be treated, and the preference and experience of the attending physician.

[0316] Non-limiting pharmaceutical compositions and methods for their preparation are described below.

[0317] Pharmaceutical compositions for oral administration

[0318] In a preferred embodiment, the present disclosure provides a pharmaceutical composition for oral administration, which contains: a compound of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114 as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient suitable for administration.

[0319] In a preferred embodiment, the present disclosure provides a solid pharmaceutical composition for oral administration, which contains: (i) an effective amount of a compound of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114 or a pharmaceutically acceptable salt thereof, and (ii) a pharmaceutical excipient suitable for administration. In some embodiments, the composition further contains (iii) an effective amount of other active pharmaceutical ingredients. For example, the other active pharmaceutical ingredients used herein may include one or more compounds that regulate AMPK activity. In some embodiments, the one or more compounds activate AMPK activity. In some embodiments, the one or more compounds phosphorylate AMPK and / or are AMPK agonists. In some embodiments, the one or more compounds inhibit AMPK activity. In some embodiments, the one or more compounds are competitive inhibitors and / or allosteric inhibitors that prevent AMPK from catalyzing the reaction.

[0320] In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral administration.

[0321] Pharmaceutical compositions of the present disclosure suitable for oral administration can be presented as discrete dosage forms, such as capsules, sachets or tablets, or liquid or aerosol sprays, each containing a predetermined amount of active ingredient, in the form of powder or granules, suspensions in solutions or aqueous or non-aqueous liquids, oil-in-water emulsions, water-in-oil liquid emulsions, powders for reconstitution, powders for oral administration, bottles (including powders or liquids in bottles), oral dissolving films, lozenges, pastes, tubes, chewing gums and packaging. Such dosage forms can be prepared by any pharmaceutical method, but all methods include the step of combining the active ingredient with a carrier constituting one or more essential ingredients. Generally speaking, the composition is prepared by uniformly and closely mixing the active ingredient with a liquid carrier or a fine solid carrier or both, and then molding the product into a desired presentation form when necessary. For example, tablets can be prepared optionally with one or more auxiliary ingredients by compression or molding. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form (e.g., powder or granules), optionally mixed with an excipient (e.g., but not limited to, a binder, a lubricant, an inert diluent, and / or a surfactant or dispersant). Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[0322] Since water can promote the degradation of certain compounds, the present disclosure also includes anhydrous pharmaceutical compositions and dosage forms. For example, water (e.g., 5%) can be added in the pharmaceutical field as a means of simulating long-term storage to determine properties such as shelf life or stability of the formulation over time. Anhydrous pharmaceutical compositions and dosage forms of the present disclosure can be prepared using anhydrous or low-water content ingredients and low moisture or low humidity conditions. If it is expected that a large amount of contact with moisture and / or humidity will occur during manufacture, packaging, and / or storage, the pharmaceutical compositions and dosage forms of the present disclosure containing lactose can be made anhydrous. Anhydrous pharmaceutical compositions can be prepared and stored to maintain their anhydrous properties. Therefore, anhydrous compositions can be packaged using materials known to prevent exposure to water so that they can be included in suitable preparation kits. Examples of suitable packaging include, but are not limited to, sealed foil, plastic or the like, unit dose containers, blister packages, and strip packages.

[0323] According to conventional pharmaceutical mixing techniques, active pharmaceutical ingredients can be closely mixed with pharmaceutical carriers. Depending on the form of the preparation required for administration, the carrier can take a variety of forms. In the preparation of oral dosage forms, any commonly used pharmaceutical medium can be used as a carrier, for example, in the case of oral liquid preparations (such as suspensions, solutions and elixirs) or aerosols, water, ethylene glycol, oil, alcohol, flavoring agents, preservatives, colorants, etc. can be used; or in the case of oral solid preparations, carriers such as starch, sugar, microcrystalline cellulose, diluents, granulating agents, lubricants, binders and disintegrants can be used, and lactose is not used in some embodiments. For example, suitable carriers include powders, capsules and tablets, as well as solid oral preparations. If necessary, tablets can be coated by standard aqueous or non-aqueous techniques.

[0324] Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch or other starches, gelatin, natural and synthetic gums (e.g., acacia), sodium alginate, alginic acid, other alginates, powdered tragacanth gum, guar gum, cellulose and its derivatives (e.g., ethylcellulose, cellulose acetate, calcium carboxymethylcellulose, sodium carboxymethylcellulose), polyvinylpyrrolidone, methylcellulose, pregelatinized starch, hydroxypropyl methylcellulose, microcrystalline cellulose, and mixtures thereof.

[0325] Examples of fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextran, kaolin, mannitol, silicic acid, sorbitol, starch, pregelatinized starch, and mixtures thereof.

[0326] Disintegrants can be used in the compositions of the present disclosure to provide tablets that disintegrate when exposed to an aqueous environment. Too much disintegrant may cause the tablet to disintegrate in the bottle. Too little may not be enough to disintegrate, thereby changing the release rate and extent of the active ingredient in the dosage form. Therefore, a sufficient amount of disintegrant can be used to form the dosage form of the compound disclosed herein, and the disintegrant is neither too little nor too much, and will not adversely change the release of the active ingredient. The amount of disintegrant can vary according to the type of formulation and the mode of administration, and can be easily distinguished by a person of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant can be used in the pharmaceutical composition, or about 1 to about 5 weight percent of disintegrant. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the present disclosure include, but are not limited to, agar, alginic acid, calcium carbonate, microcrystalline cellulose, cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, polycrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pregelatinized starch, other starches, clays, other algins, other celluloses, gums, or mixtures thereof.

[0327] Lubricants that can be used to form pharmaceutical compositions and dosage forms of the present disclosure include, but are not limited to, calcium stearate, magnesium stearate, sodium stearyl fumarate, mineral oil, light mineral oil, glycerol, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower seed oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, or mixtures thereof. Other lubricants include, for example, syloid silica gel, a condensed aerosol of synthetic silicon dioxide, silicified microcrystalline cellulose, or mixtures thereof. Lubricants may be optionally added in an amount less than about 0.5% or less than about 1% (by weight) of the pharmaceutical composition.

[0328] When oral aqueous suspensions and / or elixirs are desired, the active pharmaceutical ingredient may be combined with various sweetening or flavoring agents, colorants or dyes and, if desired, emulsifying and / or suspending agents and diluents such as water, ethanol, propylene glycol, glycerin, and various combinations thereof.

[0329] Tablets may be uncoated or may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, and thereby provide a lasting effect over a longer period of time. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be used. Preparations for oral use may also be presented as hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent (e.g., calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules, wherein the active ingredient is mixed with water or an oil medium (e.g., peanut oil, liquid paraffin or olive oil).

[0330] Surfactants that can be used to form the pharmaceutical compositions and dosage forms of the present disclosure include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants can be used, a mixture of lipophilic surfactants can be used, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant can be used.

[0331] Suitable hydrophilic surfactants generally have an HLB value of at least 10, while suitable lipophilic surfactants generally have an HLB value of about 10 or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of nonionic amphiphilic compounds is the hydrophile-lipophile balance ("HLB" value). Surfactants with lower HLB values ​​are more lipophilic or hydrophobic and have greater solubility in oils, while surfactants with higher HLB values ​​are more hydrophilic and have greater solubility in aqueous solutions. Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic or zwitterionic compounds for which the HLB standard is generally not applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, the HLB value of a surfactant is only a rough guide that is generally used to formulate industrial, pharmaceutical and cosmetic emulsions.

[0332] The hydrophilic surfactant may be ionic or nonionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidates; fatty acid derivatives of amino acids, oligopeptides and polypeptides; glyceride derivatives of amino acids, oligopeptides and polypeptides; lecithin and hydrogenated lecithin; lysolecithin and hydrogenated lysolecithin; phospholipids and their derivatives; lysolecithin and their derivatives; carnitine fatty acid ester salts; alkyl sulfates; fatty acid salts; sodium docusate; acyl lactylates; monoacetylated and diacetylated tartaric acid esters of monoglycerides and diglycerides; succinylated monoglycerides and diglycerides; citric acid esters of monoglycerides and diglycerides; and mixtures thereof.

[0333] In the above group, ionic surfactants include, for example: lecithin, lysolecithin, phospholipids, lysophospholipids and their derivatives; carnitine fatty acid ester salts; alkyl sulfates; fatty acid salts; sodium docusate; acyl lactylations; monoacetylated and diacetylated tartaric acid esters of monoglycerides and diglycerides; succinylated monoglycerides and diglycerides; citric acid esters of monoglycerides and diglycerides; and mixtures thereof.

[0334] The ionic surfactant can be an ionized form of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactic acid esters of fatty acids, stearoyl-2-lactate, stearoyl lactylate, succinylated monoglycerides, mono / diacetylated tartaric acid esters of mono / diglycerides, citrate esters of mono / diglycerides, cholylsarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linolenate, stearate, dodecyl sulfate, tetradecyl sulfate, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and salts and mixtures thereof.

[0335] The hydrophilic nonionic surfactant may include, but is not limited to, alkyl glucosides; alkyl maltosides; alkyl thioglucosides; lauryl polyethylene glycol glycerides; polyoxyalkylene alkyl ethers, such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols, such as polyethylene glycol alkylphenols; polyoxyalkylene alkylphenol fatty acid esters, such as polyethylene glycol fatty acid monoesters and polyethylene glycol fatty acid diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters, such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of polyols with at least one of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; polyoxyethylene sterols, derivatives and analogs thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of polyols with at least one of triglycerides, vegetable oils and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol or a sugar.

[0336] Other hydrophilic nonionic surfactants include, but are not limited to, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 triolein, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel Oil, PEG-50 Hydrogenated Castor Oil, PEG-40 Castor Oil, PEG-35 Castor Oil, PEG-60 Castor Oil, PEG-40 Hydrogenated Castor Oil, PEG-60 Hydrogenated Castor Oil, PEG-60 Corn Oil, PEG-6 Caprylate / Caprylate Glycerides, PEG-8 Caprylate / Caprylate Glycerides, Polyglyceryl-10 Laurate, PEG-30 Cholesterol, PEG-25 Plant Sterols, PEG-30 Soybean Sterols, PEG-20 Trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopherol PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonylphenol series, PEG 15-100 octylphenol series and poloxamer.

[0337] Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acid esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of monoglycerides and diglycerides; hydrophobic transesterification products of polyols with at least one of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins / vitamin derivatives; and mixtures thereof. In this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters and mixtures thereof, or hydrophobic transesterification products of polyols with at least one of vegetable oils, hydrogenated vegetable oils and triglycerides.

[0338] In one embodiment, the composition can include a solubilizing agent to ensure good solubilization and / or dissolution of the disclosed compound and to minimize precipitation of the disclosed compound. This is particularly important for compositions for non-oral use (e.g., compositions for injection). A solubilizing agent can also be added to increase the solubility of hydrophilic drugs and / or other components (e.g., surfactants), or to keep the composition as a stable or uniform solution or dispersion.

[0339] Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycol having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; amides and other nitrogen-containing compounds, such as 2-pyrrolidone, 2-piperidone, ε-caprolactone, 2-hydroxy-1 ... Amines, N-alkylpyrrolidones, N-hydroxyalkylpyrrolidones, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, triethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and its isomers, δ-valerolactone and its isomers, β-butyrolactone and its isomers; and other solubilizers known in the art, such as dimethylacetamide, dimethyl isosorbide, N-methylpyrrolidone, caprylic acid monoglyceride, diethylene glycol monoethyl ether and water.

[0340] Mixtures of solubilizing agents may also be used. Examples include, but are not limited to, triacetin, triethyl citrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methyl pyrrolidone, N-hydroxyethyl pyrrolidone, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrin, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizing agents include sorbitol, glycerol, triacetin, ethanol, PEG-400, glycofurol, and propylene glycol.

[0341] The amount of the solubilizing agent that can be included is not particularly limited.The amount of a given solubilizing agent may be limited to biologically acceptable amount, which can be easily determined by those skilled in the art.In some cases, it may be advantageous to add a solubilizing agent that far exceeds biologically acceptable amount, for example, in order to maximize drug concentration, before compositions is provided to the patient, conventional techniques (such as distillation or evaporation) are used to remove excessive solubilizing agent.Therefore, if present, the weight ratio of solubilizing agent can be 10 % by weight, 25 % by weight, 50 % by weight, 100 % by weight or up to about 200 % by weight of the gross weight based on medicine and other excipients.If desired, a very small amount of solubilizing agent can also be used, for example 5%, 2%, 1% or even less.Usually, the amount of solubilizing agent can be about 1 % by weight to about 100 % by weight, more typically about 5 % by weight to about 25 % by weight.

[0342] The composition may also contain one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, but are not limited to, anti-adhesives, defoamers, buffers, polymers, antioxidants, preservatives, chelating agents, viscosity modifiers, tension modifiers, flavoring agents, colorants, flavoring agents, opacifiers, suspending agents, adhesives, fillers, plasticizers, lubricants, and mixtures thereof.

[0343] In addition, acid or base can be added to the composition to facilitate processing, enhance stability or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium bicarbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris (hydroxymethyl) aminomethane (TRIS) and the like. Suitable bases are also pharmaceutically acceptable acid salts, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkylsulfonic acid, amino acid, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acid, formic acid, fumaric acid, gluconic acid, hydroquinonesulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, p-bromobenzenesulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, etc. Also polyacid salts can be used, such as sodium phosphate, disodium hydrogen phosphate and sodium dihydrogen phosphate. When the base is a salt, the cation can be any convenient, pharmaceutically acceptable cation, such as ammonium, alkali metals and alkaline earth metals. Examples may include, but are not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.

[0344] Suitable acid is a pharmaceutically acceptable organic acid or inorganic acid. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, etc. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkylsulfonic acid, amino acid, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acid, formic acid, fumaric acid, gluconic acid, hydroquinonesulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid and uric acid.

[0345] Pharmaceutical composition for injection

[0346] In a preferred embodiment, the present disclosure provides a pharmaceutical composition for injection, which contains: a compound of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114 as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient suitable for injection. The components and amounts of the compounds in the composition are as described herein.

[0347] The compositions of the present invention may be incorporated into forms for injectable administration including aqueous or oily suspensions or emulsions, containing sesame oil, corn oil, cottonseed oil or peanut oil, as well as elixirs, mannitol, glucose or sterile aqueous solutions and similar pharmaceutical carriers.

[0348] Aqueous solutions in saline are also commonly used for injection. Ethanol, glycerol, propylene glycol and liquid polyethylene glycol (and suitable mixtures thereof), cyclodextrin derivatives and vegetable oils may also be used. Suitable fluidity may be maintained, for example, by the use of a coating such as lecithin to maintain the desired particle size in the case of a dispersion and by the use of a surfactant. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid and thimerosal.

[0349] Sterile injection solutions are prepared by adding the compounds of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114, or their pharmaceutically acceptable salts, in the required amount to an appropriate solvent, and adding the various other ingredients listed above as required, followed by filtration sterilization. Dispersions are generally prepared by incorporating a variety of sterilized active ingredients into a sterile vehicle containing an alkaline dispersion medium and the required other ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying techniques and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0350] Pharmaceutical compositions for topical delivery

[0351] In a preferred embodiment, the present disclosure provides a pharmaceutical composition for transdermal delivery, which contains: a compound of formula (I), formula (10) to (17), formula (20) to (26), formula (100) to (190), formula (200) to (270), formula (300) to (370), formula (400) to (470), formula (500) to (570), formula (600) to (670), formula (700) to (770), formula (800) to (870), formula (900) to (970), and formula 1001 to 1114 as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient suitable for transdermal delivery.

[0352] The compositions of the present disclosure can be formulated into solid, semisolid or liquid preparations suitable for topical or topical administration, such as gels, water-soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethyl sulfoxide (DMSO)-based solutions. In general, carriers with higher density can provide a longer exposure to the active ingredient for a certain area. In contrast, solution formulations can expose the active ingredient to a selected area faster.

[0353] The pharmaceutical composition can also include suitable solid or gel phase carriers or excipients, which are compounds that allow the permeability of therapeutic molecules to be increased through the permeability barrier of the stratum corneum of the skin or help deliver therapeutic molecules through the permeability barrier of the stratum corneum of the skin. For those skilled in the art of topical preparations, it is known that there are many such penetration enhancing molecules. Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidone, monolaurin, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers (e.g., polyethylene glycol).

[0354] Another exemplary formulation for the disclosed methods employs a transdermal delivery device ("patch"). Such transdermal patches can be used to continuously or discontinuously infuse a compound of Formula (I), Formulas (10) to (17), Formulas (20) to (26), Formulas (100) to (190), Formulas (200) to (270), Formulas (300) to (370), Formulas (400) to (470), Formulas (500) to (570), Formulas (600) to (670), Formulas (700) to (770), Formulas (800) to (870), Formulas (900) to (970), Formulas 1001 to 1114, or a pharmaceutically acceptable salt thereof, as described herein, with or without another active pharmaceutical ingredient.

[0355] The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252; 4,992,445; and 5,001,139. ​​Such patches may be constructed for continuous, pulsatile, or on-demand delivery of an agent.

[0356] Pharmaceutical composition for inhalation

[0357] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. Preferably, the composition is administered by oral or nasal respiratory route to obtain local or systemic effects. Compositions in preferred pharmaceutically acceptable solvents can be atomized by using an inert gas. The atomized solution can be inhaled directly from the atomizing device, or the atomizing device can be connected to a face mask (face mask tent) or an intermittent positive pressure breathing machine. Solutions, suspensions or powder compositions can be administered by devices that deliver the preparations in an appropriate manner, preferably orally or nasally. Dry powder inhalers can also be used to provide inhalation delivery of the composition.

[0358] Other pharmaceutical compositions

[0359] Pharmaceutical compositions can also be prepared from the compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural or intraspinal administration. The preparation of such pharmaceutical compositions is well known in the art. See, for example, Anderson et al., eds., Handbook of Clinical Drug Data, 10th edition, McGraw-Hill, 2002; and Pratt and Taylor, eds., Principles of Drug Action, 3rd edition, Churchill Livingston, NY, 1990, each of which is incorporated herein by reference in its entirety.

[0360] The compounds of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114, or their pharmaceutically acceptable salts, or pharmaceutical compositions of these compounds, as described herein, can be administered by any method capable of delivering the compound to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g., transdermal application), rectal administration, local delivery via a catheter or stent, or by inhalation. The compounds of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), and Formula 1001 to 1114 described herein, or their pharmaceutically acceptable salts, can also be administered intraperitoneally or intrathecally.

[0361] Compositions of the present disclosure can also be delivered by impregnating or coating devices (e.g., stents) or cylindrical polymers inserted into arteries. Such methods of administration can, for example, help prevent or improve restenosis after surgeries such as balloon angioplasty. Without being bound by theory, compounds of the present disclosure can slow down or inhibit the migration and proliferation of smooth muscle cells in the arterial wall that cause restenosis. Compounds of the present disclosure can be applied by, for example, local delivery from the struts of the stent, from stent grafts, from grafts, or from the covering or sheath of the stent. In some embodiments, compounds of the present disclosure are mixed with a matrix. Such a matrix can be a polymer matrix, and can be used to bond the compound to the stent. Suitable polymer matrices for such uses include, for example, lactone-based polyesters or copolyesters, such as polylactide, polycaprolactone, polyorthoesters, polyanhydrides, polyamino acids, polysaccharides, polyphosphazenes, poly(ether-ester) copolymers (e.g., PEO-PLLA); polydimethylsiloxane, poly(ethylene-vinyl acetate), acrylate-based polymers or copolymers (e.g., polyhydroxyethyl methyl methacrylate, polyvinyl pyrrolidone), fluorinated polymers (e.g., polytetrafluoroethylene), and cellulose esters. Suitable matrices may be non-degradable or may degrade over time to release one or more compounds. The compounds of Formula (I), Formulas (10) to (17), Formulas (20) to (26), Formulas (100) to (190), Formulas (200) to (270), Formulas (300) to (370), Formulas (400) to (470), Formulas (500) to (570), Formulas (600) to (670), Formulas (700) to (770), Formulas (800) to (870), Formulas (900) to (970), Formulas 1001 to 1114 described herein, or pharmaceutically acceptable salts thereof, can be applied to the surface of the stent by various methods, such as dip / spin coating, spray coating, dip coating, and / or brush coating. The compound can be applied to a solvent and then the solvent is allowed to evaporate, thereby forming a layer of the compound on the stent. Alternatively, the compound can be located in the body of the stent or graft, such as in a microchannel or micropore. After implantation, the compound diffuses out of the body of the stent and contacts the arterial wall. Such stents can be prepared by immersing a manufactured stent containing such micropores or microchannels in a solution of the disclosed compound in a suitable solvent and then evaporating the solvent. The excess drug on the stent surface can be removed by an additional short solvent wash. In other embodiments, the disclosed compound can be covalently attached to a stent or graft. A covalent linker that degrades in vivo can be used to cause the release of the disclosed compound. Any biologically unstable connection can be used for this purpose, such as an ester, amide or anhydride connection.The compounds of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), and (1001 to 1114 described herein, or their pharmaceutically acceptable salts, may also be administered intravascularly from a balloon used during angioplasty. The compounds of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), and (1001 to 1114 described herein, or their pharmaceutically acceptable salts, may also be administered extravascularly via the pericardium or via external application of the formulations disclosed herein to reduce restenosis.

[0362] Exemplary parenteral administration forms include solutions or suspensions of compounds of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), or (1001 to 1114, or pharmaceutically acceptable salts thereof, in sterile aqueous solution (e.g., aqueous propylene glycol or aqueous dextrose). Such dosage forms may be suitably buffered, if desired.

[0363] The present disclosure also provides a kit. The kit includes a compound of Formula (I), Formulas (10) to (17), Formulas (20) to (26), Formulas (100) to (190), Formulas (200) to (270), Formulas (300) to (370), Formulas (400) to (470), Formulas (500) to (570), Formulas (600) to (670), Formulas (700) to (770), Formulas (800) to (870), Formulas (900) to (970), Formulas 1001 to 1114, or a pharmaceutically acceptable salt thereof, as described herein, in suitable packaging, and written materials, which may include instructions for use, a discussion of clinical studies, and a list of side effects. Such kits may also include information such as scientific literature references, package insert materials, clinical trial results, and / or summaries of these contents, which indicate or determine the activity and / or advantages of the composition, and / or describe dosage, administration, side effects, drug interactions, or other information useful to healthcare providers. Such information may be based on the results of various studies (e.g., studies using experimental animals involving in vivo models and studies based on human clinical trials). The kit may also contain another active pharmaceutical ingredient. In some embodiments, the compounds of Formula (I), Formulas (10) to (17), Formulas (20) to (26), Formulas (100) to (190), Formulas (200) to (270), Formulas (300) to (370), Formulas (400) to (470), Formulas (500) to (570), Formulas (600) to (670), Formulas (700) to (770), Formulas (800) to (870), Formulas (900) to (970), Formulas 1001 to 1114 described herein, or pharmaceutically acceptable salts thereof, and another active pharmaceutical ingredient are provided as separate compositions in separate containers within the kit. In some embodiments, the compounds of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114, or pharmaceutically acceptable salts thereof, and the agent are provided as a single composition within a kit container. Suitable packaging and additional items for use (e.g., measuring cups for liquid formulations, foil packaging to minimize exposure to air, etc.) are known in the art and may be included in the kit. The kits described herein may be provided, sold, and / or promoted to healthcare providers (including physicians, nurses, pharmacists, pharmacy officers, etc.). In some embodiments, the kits can also be sold directly to consumers.

[0364] The above kits are preferably used to treat the diseases and disorders described herein. In some embodiments, the kits described herein are used to treat mitochondrial dysfunction. In some embodiments, the mitochondrial dysfunction is primary mitochondrial dysfunction. In some embodiments, selected from the group consisting of: autosomal dominant optic atrophy (ADOA), Alpers-Huttenlocher syndrome (nDNA defect), ataxia neuropathy syndrome (nDNA defect), Barth syndrome / lethal infantile cardiomyopathy (LIC), coenzyme Q deficiency, complex I, complex II, complex III, complex IV and complex V deficiency (single deficiency or any deficiency combination), chronic progressive external ophthalmoplegia (CPEO), diabetes and deafness, Kearns-Sayre syndrome (mtDNA defect), leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate (LBSL-leukodystrophy), Leigh syndrome (mtDNA and nDNA defects), Leber hereditary optic neuropathy (LHON), Luf t disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke syndrome (MELAS) (mtDNA defect), mitochondrial enoyl-CoA reductase protein-associated neurodegeneration (MEPAN), myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial recessive ataxia syndrome (MIRAS), mtDNA deletion syndrome, mtDNA depletion syndrome, mtDNA maintenance disorder, mtDNA / RNA translation defect, mitochondrial tRNA synthetase defect, mitochondrial myopathy, mitochondrial neurogastroenteric encephalopathy syndrome (MNGIE), neurogenic myasthenia, ataxia and retinitis pigmentosa (NARP), Pearson syndrome, pyruvate dehydrogenase complex deficiency (PDCD / PDH), DNA polymerase gamma deficiency (POLG), pyruvate carboxylase deficiency and thymidine kinase 2 deficiency (TK2). In some embodiments, the mitochondrial dysfunction is secondary mitochondrial dysfunction.In some embodiments, the secondary mitochondrial dysfunction is selected from the group consisting of: age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and other dementias, Friedreich's ataxia (FA), Huntington's disease (HD), motor neuron disease (MND), N-glycanase deficiency (NGLY1), organic acidemias, Parkinson's disease (PD) and PD-related disorders, prion diseases, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA), Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, Em ery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, Charcot-Marie-Tooth disease, congenital myopathies, distal myopathies, endocrine myopathies (hyperthyroid myopathy, hypothyroid myopathy), giant axonal neuropathy, hereditary spastic paraplegia, inflammatory myopathies (dermatomyositis, inclusion body myositis, polymyositis), metabolic myopathies, neuromuscular junction disorders, autism, cancer, diabetes, metabolic syndrome, chronic fatigue syndrome, inflammatory disorders, arthritis, aging, and mitochondrial epilepsy (epilepsy secondary to primary mitochondrial disease).

[0365] Dosage and administration schedule

[0366] The amount of the compound of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), (1001 to 1114) described herein, or a pharmaceutically acceptable salt thereof, administered depends on the human or mammal being treated, the severity of the condition or disorder, the rate of administration, the disposition of the compound, and the judgment of the prescribing physician. However, an effective dosage range for each drug is from about 0.001 to about 100 mg per kilogram of body weight per day, for example, from about 1 to about 35 mg / kg / day, administered in a single or divided dose. For a 70 kg person, this would amount to about 0.05 to 7 g / day, for example, about 0.05 to about 2.5 g / day. In some cases, dosage levels below the lower limit of the above range may be more than adequate, while in other cases larger doses may be used without causing any harmful side effects, for example by dividing such larger doses into several smaller doses for administration throughout the day. The dosage of the compounds of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), (1001 to 1114 as described herein, or their pharmaceutically acceptable salts, may be expressed in mg / kg body weight or mg / m 2 The units are provided in terms of body surface area.

[0367] In some embodiments, the compounds of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), and Formula 1001 to 1114 described herein, or their pharmaceutically acceptable salts, are administered in multiple doses. In a preferred embodiment, the compounds of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114, or pharmaceutically acceptable salts thereof, described herein, are administered in multiple doses. Administration may be once, twice, three times, four times, five times, six times, or more per day. Administration may be once a month, once every two weeks, once a week, or once every other day. In other embodiments, the compounds of Formula (I), (10)-(17), (20)-(26), (100)-(190), (200)-(270), (300)-(370), (400)-(470), (500)-(570), (600)-(670), (700)-(770), (800)-(870), (900)-(970), and (1001-1114 described herein, or pharmaceutically acceptable salts thereof, are administered about once a day to about 6 times a day.In some embodiments, the compounds of Formula (I), (10)-(17), (20)-(26), (100)-(190), (200)-(270), (300)-(370), (400)-(470), (500)-(570), (600)-(670), (700)-(770), (800)-(870), (900)-(970), and (1001-1114 described herein, or their pharmaceutically acceptable salts, are administered once daily, while in other embodiments, the compounds of Formula (I), (10)-(17), (20)-(26), (100)-(190), (200)-(270), (300)-(370), (400)-(470), (500)-(570), (600)-(670), (700)-(770), (800)-(870), (900)-(970), and (1001-1114 described herein, or their pharmaceutically acceptable salts, are administered once daily. In some embodiments, the compounds of Formula (I), (10)-(17), (20)-(26), (100)-(190), (200)-(270), (300)-(370), (400)-(470), (500)-(570), (600)-(670), (700)-(770), (800)-(870), (900)-(970), and (1001-1114, or their pharmaceutically acceptable salts, are administered twice daily, and in other embodiments, the compounds of Formula (I), (10)-(17), (20)-(26), (100)-(190), (200)-(270), (300)-(370), (400)-(470), (500)-(570), (600)-(670), (700)-(770), (800)-(870), (900)-(970), and (1001-1114, or their pharmaceutically acceptable salts, are administered three times daily.

[0368] Administration of the compounds of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), and (1001 to 1114 described herein, or their pharmaceutically acceptable salts, can be continued as necessary. In some embodiments, the compounds of Formula (I), (10)-(17), (20)-(26), (100)-(190), (200)-(270), (300)-(370), (400)-(470), (500)-(570), (600)-(670), (700)-(770), (800)-(870), (900)-(970), and (1001-1114 described herein, or their pharmaceutically acceptable salts, are administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, the administration time of the compounds of Formula (I), (10)-(17), (20)-(26), (100)-(190), (200)-(270), (300)-(370), (400)-(470), (500)-(570), (600)-(670), (700)-(770), (800)-(870), (900)-(970), and (1001-1114 described herein, or their pharmaceutically acceptable salts, is less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, the compounds of Formula (I), (10)-(17), (20)-(26), (100)-(190), (200)-(270), (300)-(370), (400)-(470), (500)-(570), (600)-(670), (700)-(770), (800)-(870), (900)-(970), and (1001-1114 described herein, or pharmaceutically acceptable salts thereof, are administered chronically on an ongoing basis, for example, for the treatment of chronic effects.In another embodiment, the administration of the compounds of Formula (I), (10)-(17), (20)-(26), (100)-(190), (200)-(270), (300)-(370), (400)-(470), (500)-(570), (600)-(670), (700)-(770), (800)-(870), (900)-(970), (1001-1114) or their pharmaceutically acceptable salts described herein lasts for less than about 7 days. In yet another embodiment, the administration lasts for more than about 6, 10, 14, 28 days, two months, six months or one year. In some cases, continuous administration can be achieved and maintained for as long as necessary.

[0369] In some embodiments, the effective dose of the compound of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula (1001 to 1114, or a pharmaceutically acceptable salt thereof, as described herein, is in the range of about 1 mg to about 500 mg, about 10 mg to about 300 mg, about 20 mg to about 250 mg, about 25 mg to about 200 mg, about 10 mg to about 200 mg, about 20 mg to about about 150 mg, about 30 mg to about 120 mg, about 10 mg to about 90 mg, about 20 mg to about 80 mg, about 30 mg to about 70 mg, about 40 mg to about 60 mg, about 45 mg to about 55 mg, about 48 mg to about 52 mg, about 50 mg to about 150 mg, about 60 mg to about 140 mg, about 70 mg to about 130 mg, about 80 mg to about 120 mg, about 90 mg to about 110 mg, about 95 mg to about 105 mg, about 150 mg to about 250 mg, about 160 mg to about 240 mg, about 170 mg to about 230 mg, about 180 mg to about 220 mg, about 190 mg to about 210 mg, about 195 mg to about 205 mg, or about 198 to about 202 mg.

[0370] In some embodiments, the compounds of Formula (I), Formula (10) to (17), Formula (20) to (26), Formula (100) to (190), Formula (200) to (270), Formula (300) to (370), Formula (400) to (470), Formula (500) to (570), Formula (600) to (670), Formula (700) to (770), Formula (800) to (870), Formula (900) to (970), Formula 1001 to 1114 described herein, or pharmaceutically acceptable salts thereof An effective dosage of the salt is in the range of about 0.01 mg / kg to about 4.3 mg / kg, about 0.15 mg / kg to about 3.6 mg / kg, about 0.3 mg / kg to about 3.2 mg / kg, about 0.35 mg / kg to about 2.85 mg / kg, about 0.15 mg / kg to about 2.85 mg / kg, about 0.3 mg to about 2.15 mg / kg, about 0.45 mg / kg to about 1.7 mg / kg, about 0.15 mg / kg to about 1.3 mg / kg, about 0. 3mg / kg to about 1.15mg / kg, about 0.45mg / kg to about 1mg / kg, about 0.55mg / kg to about 0.85mg / kg, about 0.65mg / kg to about 0.8mg / kg, about 0.7mg / kg to about 0.75mg / kg, about 0.7mg / kg to about 2.15mg / kg, about 0.85mg / kg to about 2mg / kg, about 1mg / kg to about 1.85mg / kg, about 1.15mg / kg to about 1.7mg / kg, about 1.3 mg / kg to about 1.6 mg / kg, about 1.35 mg / kg to about 1.5 mg / kg, about 2.15 mg / kg to about 3.6 mg / kg, about 2.3 mg / kg to about 3.4 mg / kg, about 2.4 mg / kg to about 3.3 mg / kg, about 2.6 mg / kg to about 3.15 mg / kg, about 2.7 mg / kg to about 3 mg / kg, about 2.8 mg / kg to about 3 mg / kg or about 2.85 mg / kg to about 2.95 mg / kg.

[0371] In some cases, dosage levels below the lower limit of the aforementioned range may be more than adequate, while in other cases larger doses may be used without causing any harmful side effects, for example by dividing such larger doses into several smaller doses for administration throughout the day.

[0372] An effective amount of a compound of Formula (I), (10) to (17), (20) to (26), (100) to (190), (200) to (270), (300) to (370), (400) to (470), (500) to (570), (600) to (670), (700) to (770), (800) to (870), (900) to (970), or (1001 to 1114 described herein, or a pharmaceutically acceptable salt thereof, can be administered by any acceptable mode of administration for agents with similar utilities, including rectal, oral, intranasal, and transdermal routes, by intraarterial injection, intravenous, intraperitoneal, parenteral, intramuscular, subcutaneous, oral, topical, or as an inhalant, in a single dose or multiple doses.

[0373] Example

[0374] The embodiments contained herein are now described with reference to the following examples. These examples are provided for illustrative purposes only, and the disclosure contained herein should in no way be construed as being limited to these examples, but rather should be construed to encompass any and all variations that become apparent as a result of the teachings provided herein.

[0375] Example 1: Synthesis of the disclosed compounds

[0376] General synthetic route R-1

[0377]

[0378] Any amide coupling reagent known in the art can be used to achieve the coupling of indole and hydroxylamine. In an exemplary embodiment, the reagent is selected from BOP-Cl, TBTU, BOP, PyBop, HATU, EDCI / HOBT, DIC / HOBT; and DCC / HOBT.

[0379] A. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (1003)

[0380]

[0381] Compound 1003 was prepared according to general synthetic route R-1. DIPEA (0.4 mL, 1.734 mmol) and HATU (0.34 g, 0.867 mmol) were added to a solution of 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indole-3-carboxylic acid (0.20 g, 0.578 mmol) in DMF (10 mL) at RT. O-Methylhydroxylamine (0.06 g, 0.693 mmol) was then added and the reaction mass was stirred for 48 hours. The reactant was diluted with ethyl acetate, washed with water, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to a crude product, which was purified by preparative HPLC to give 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide as an off-white solid (14 mg, 11%).

[0382] LCMS :99.81%(M / Z 373.15,[MH] + )

[0383] 1 H NMR; 400MHz, DMSO-d6: δ11.42(br,2H),7.93(s,1H),7.92(s,1H),7.55(s,1H),7.3 1(d,J=8.40Hz,1H),6.22(d,J=8.00Hz,1H),3.76(s,3H),3.69(s,3H),3.07(s,6H).

[0384] B. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-ethoxy-1H-indole-3-carboxamide (1009)

[0385]

[0386] Compound 1009 was prepared according to general synthetic route R-1 using an experimental procedure similar to that used to prepare 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (compound 1003).

[0387] LCMS :99.12%(M / Z 387.26,[MH])

[0388] 1H NMR 400MHz, DMSO-d6: δ11.65-11.15(br s,2H),7.95(s,1H),7.92(s,1H),7.56(s,1H),7.31(d,J=8.00Hz,1H),6.22(d,J=8.40 Hz, 1H), 3.93-3.88 (q, J = 6.8Hz, 2H), 3.76 (s, 3H), 3.07 (s, 6H), 1.20 (t, J = 7.2Hz, 3H).

[0389] C. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-isopropoxy-1H-indole-3-carboxamide (1010)

[0390]

[0391] Compound 1010 was prepared according to general synthetic route R-1 using an experimental procedure similar to that used to prepare 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (compound 1003).

[0392] LCMS :99.16%(M / Z 403.34,[M+H]+)

[0393] 1 H NMR : 400MHz, DMSO-d6: δ11.66(s,1H),10.86(s,1H),7.97(d,J=2.80Hz,1H),7.93(s,1H),7.54(s,1H),7.31(d, J=8.00Hz,1H),6.22(d,J=8.00Hz,1H),4.11-4.04(m,1H),3.76(s,3H),3.07(s,6H),1.19(d,J=6.40Hz,6H).

[0394] D. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-(2-methoxyethoxy)-1H-indole-3-carboxamide (1011)

[0395]

[0396] Compound 1011 was prepared according to general synthetic route R-1 using an experimental procedure similar to that used to prepare 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (compound 1003).

[0397] LCMS:99.61%(M / Z 419.39,[M+H]+)

[0398] 1 H NMR : 400MHz, DMSO-d6: δ11.68(s,1H),11.12(s,1H),7.98(s,1H),7.93(s,1H),7.54(s,1H),7.31(d,J=8.00Hz,1H) ,6.22(d,J=8.00Hz,1H),3.99(t,J=4.80Hz,2H),3.76(s,3H),3.57(t,J=4.40Hz,2H),3.32(s,3H),3.07(s,6H).

[0399] E. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-phenoxy-1H-indole-3-carboxamide (1012)

[0400]

[0401] Compound 1012 was prepared according to general synthetic route R-1 using an experimental procedure similar to that used to prepare 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (compound 1003).

[0402] LCMS :97.14%(M / Z 437.36,[M+H]+)

[0403] 1 H NMR : 400MHz, DMSO-d6: δ11.83(s,2H),8.10(s,1H),7.92(s,1H),7.59(s,1H),7.35-7.30(m,3H),7 .09(d,J=8.00Hz,2H),7.01(t,J=7.2Hz,1H),6.21(d,J=8.40Hz,1H),3.76(s,3H),3.06(s,6H).

[0404] F. Synthesis of 6-chloro-N-(cyclohexyloxy)-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indole-3-carboxamide (1013)

[0405]

[0406] Compound 1013 was prepared according to general synthetic route R-1 using an experimental procedure similar to that used to prepare 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (compound 1003).

[0407] LCMS: 96.97% (443.29, M+H);

[0408] 1 H NMR 400MHz, DMSO-d6: δ11.68(s,1H),10.89(s,1H),7.97(s,1H),7.93(s,1H),7.54(s,1H),7.31(d,J=8.00Hz,1H),6 .22(d,J=8.00Hz,1H),3.79-3.76(m,4H),3.07(s,6H),1.91-1.89(m,2H),1.73-1.71(m,2H),1.39-1.21(m,6H).

[0409] Synthesis of GN-(tert-Butyloxy)-6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indole-3-carboxamide (1014)

[0410]

[0411] Compound 1014 was prepared according to general synthetic route R-1 using an experimental procedure similar to that used to prepare 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (compound 1003).

[0412] LCMS :99.43%(M / Z 417.41,[M+H]+)

[0413] 1 H NMR 400MHz, DMSO-d6: δ11.66(s,1H),10.40(s,1H),8.02(s,1H),7.92(s,1H),7.54(s,1H), 7.31(d,J=8.40Hz,1H), 6.22(d,J=8.40Hz,1H), 3.76(s,3H), 3.07(s,6H), 1.22(s,9H).

[0414] H. Synthesis of 6-chloro-N-(cyclopropylmethoxy)-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indole-3-carboxamide (1015)

[0415]

[0416] Compound 1015 was prepared according to general synthetic route R-1 using an experimental procedure similar to that used to prepare 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (compound 1003).

[0417] LCMS : 98.86% (M+H=415.69)

[0418] 1 H NMR (400MHz, DMSO-d6): δ11.66(d,J=2.00Hz,1H),11.05(s,1H),7.94(t,J=2.40Hz,1H),7.54(s,1H),7.31(d,J=8.00Hz,1H),6. 22(d,J=8.00Hz,1H),3.76(s,3H),3.69(d,J=7.20Hz,2H),3.07(s,6H),1.14-1.07(m,1H),0.56-0.54(m,2H),0.34-0.32(m,2H).

[0419] Synthesis of IN-(Benzyloxy)-6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indole-3-carboxamide (1016)

[0420]

[0421] Compound 1016 was prepared according to general synthetic route R-1 using an experimental procedure similar to that used to prepare 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (compound 1003).

[0422] LCMS: 95.56% (451.43, M+H);

[0423] 1 H NMR (400MHz, DMSO-d6): δ11.41(br s,2H),7.93(d,J=3.20Hz,2H),7.55(s,1H),7.45-7.73(m,2H),7.38-7.3 0(m,4H),6.23(d,J=8.40Hz,1H),4.91(s,2H),3.77(s,3H),3.07(s,6H).

[0424] J. Synthesis of 4,6-difluoro-N-((tetrahydro-2H-pyran-2-yl)oxy)-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide (1026)

[0425]

[0426] Compound 1026 was prepared according to general synthetic route R-1 using an experimental procedure similar to that used to prepare 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (compound 1003).

[0427] LCMS :98.78%(MH=455.38)

[0428] 1 H NMR (400MHz, DMSO-d6): δ11.99(br,1H),7.85(s,1H),7.43-7.37(m,4H),7.23(d,J=10.40Hz,1H),4.96(s,1H),4.3 9(d,J=2.00Hz,1H),4.01-3.98(m,2H),3.59-3.48(m,2H),1.87-1.85(m,2H),1.69-1.60(m,4H),1.57-1.50(m,6H).

[0429] General synthetic route R-2

[0430]

[0431] Any Suzuki coupling conditions known in the art can be used to achieve the coupling of boronic acid / ester with aryl / heteroaryl halide. In an exemplary embodiment, the Suzuki coupling can be carried out in the presence of a palladium catalyst such as bis(tri-tert-butylphosphine)palladium, tetrakis(triphenylphosphine)palladium or a palladium cyclocatalyst (e.g., Bedford, RB and Cazin, CSJ (2001) Chem. Commun., 1540-1541) and a base (e.g., carbonate such as potassium carbonate).

[0432] K. Synthesis of 6-chloro-N-methoxy-5-(2-methoxy-6-(methylamino)pyridin-3-yl)-1H-indole-3-carboxamide (1017)

[0433]

[0434] Step 1: Synthesis of 5-bromo-6-chloro-N-methoxy-1H-indole-3-carboxamide

[0435]

[0436] To a solution of 5-bromo-6-chloro-1H-indole-3-carboxylic acid (2.0 g, 7.29 mmol) in DMF (20 mL) was added DIPEA (3.82 mL, 21.87 mmol), HATU (4.16 g, 10.94 mmol) and the reaction mixture was stirred for 15 minutes. Methoxyamine hydrochloride (1.22 g, 14.57 mmol) was added to the reaction in portions over 15 minutes and stirred at RT for 5 hours. The reaction was diluted with EtOAc (200 mL), washed with water, brine, dried over Na2SO4 and concentrated under reduced pressure to give 5-bromo-6-chloro-N-methoxy-1H-indole-3-carboxamide as an off-white solid (1.5 g; yield 67%). LCMS: 84.63% ([M+H]=303.19), which was used directly in the next step.

[0437] Step 2: Synthesis of 6-chloro-N-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-3-carboxamide

[0438] The product of step 1 (1.5 g, 4.96 mmol), Bis-Pin (1.90 g, 7.45 mmol) and KOAc (0.97 g, 9.92 mmol) in dioxane (25 mL) were purged with nitrogen for 10 minutes. Pd (OAc) 2 (56 mg, 0.248 mmol) and PCy 3 (70 mg, 0.248 mmol) were added, and after purging with nitrogen again, the reaction mixture was stirred at 80 ° C for 8 hours. The reaction mixture was then cooled to RT, diluted with EtOAc and filtered through a diatomaceous earth bed. The filtrate was concentrated under reduced pressure to give a crude 6-chloro-N-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-3-carboxamide, which was used directly in the next step.

[0439] Step 3: Synthesis of 6-chloro-N-methoxy-5-(2-methoxy-6-(methylamino)pyridin-3-yl)-1H-indole-3-carboxamide (1017)

[0440]

[0441] Compound 1017 was prepared according to general synthetic route R-2. To a stirred solution of 5-bromo-6-methoxy-N-methylpyridin-2-amine (0.25 g, 1.152 mmol) in 1,4-dioxane (5 mL) and water (1 mL) was added 6-chloro-N-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-3-carboxamide (0.5 g, 1.382 mmol) and K2CO3 (0.33 g, 2.304 mmol). The reaction mixture was purged with N2 and PdCl2(dPPf)2 and DCM (0.049 g, 0.058 mmol) were added. After stirring at 90°C for 5 hours, the reaction mixture was filtered through a celite bed and washed with ethyl acetate. The combined organic layers were concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC to afford 6-chloro-N-methoxy-5-(2-methoxy-6-(methylamino)pyridin-3-yl)-1H-indole-3-carboxamide as an off-white solid (21 mg, 5.06%).

[0442] LCMS : 95.87% (361.30, M+H);

[0443] 1 H NMR 400MHz, DMSO-d6: δ11.64(br s,1H),11.17(br s,1H),7.92(s,1H),7.91(s,1H),7.54(s,1H),7.21(d,J=8.00Hz,1H),6.49-6.45 (m,1H),6.06(d,J=8.00Hz,1H),3.74(s,3H),3.69(s,3H),2.82(d,J=4.80Hz,3H).

[0444] L. Synthesis of 6-chloro-5-(6-(cyclopropylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (1018)

[0445]

[0446] Compound 1018 was prepared according to general synthetic route R-2 using an experimental procedure similar to that used to prepare 6-chloro-N-methoxy-5-(2-methoxy-6-(methylamino)pyridin-3-yl)-1H-indole-3-carboxamide (Compound 1017).

[0447] LCMS : 93.26% (387.34, M+H);

[0448] 1H NMR (400MHz, DMSO-d6): δ11.83(br s,1H),11.13(br s,1H),7.92(m,2H),7.55(s,1H),7.29(d,J=7.60Hz,1H),6.74(s,1H),6.26(d,J=8.00Hz,1H),3.72(s,3H),3.69(s,3H),2.55(br s,1H),0.71-0.70(m,2H),0.48(br s,2H).

[0449] M. Synthesis of 5-(6-(azetidin-1-yl)-2-methoxypyridin-3-yl)-6-chloro-N-methoxy-1H-indole-3-carboxamide (1019)

[0450]

[0451] Compound 1019 was prepared according to general synthetic route R-2 using an experimental procedure similar to that used to prepare 6-chloro-N-methoxy-5-(2-methoxy-6-(methylamino)pyridin-3-yl)-1H-indole-3-carboxamide (Compound 1017).

[0452] LCMS : 97.06% (387.34, M+H);

[0453] 1 H NMR 400MHz, DMSO-d6: δ11.35(br s,2H),7.93-7.90(m,2H),7.57(s,1H),7.31(d,J=8.00Hz,1H),5.96(d,J=7.6 0Hz, 1H), 3.98 (t, J = 7.20Hz, 4H), 3.73 (s, 3H), 3.68 (s, 3H), 2.36-2.32 (m, 2H).

[0454] N. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-ethoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (1020)

[0455]

[0456] Compound 1020 was prepared according to general synthetic route R-2 using an experimental procedure similar to that used to prepare 6-chloro-N-methoxy-5-(2-methoxy-6-(methylamino)pyridin-3-yl)-1H-indole-3-carboxamide (compound 1017).

[0457] LCMS: 99.09% (389.36, M+H);

[0458] 1 H NMR 400MHz, DMSO-d6: δ11.29(br s,2H),7.93(s,2H),7.56(s,1H),7.31(d,J=8.00Hz,1H),6.20(d,J=8.00Hz,1 H), 4.28 (q, J = 6.80Hz, 2H), 3.69 (s, 3H), 3.05 (s, 6H), 1.22 (t, J = 6.80Hz, 3H).

[0459] O. Synthesis of 6-chloro-5-(4-(1-(hydroxymethyl)cyclopropyl)phenyl)-N-methoxy-1H-indole-3-carboxamide (1024)

[0460]

[0461] Compound 1024 was prepared according to general synthetic route R-2 using an experimental procedure similar to that used to prepare 6-chloro-N-methoxy-5-(2-methoxy-6-(methylamino)pyridin-3-yl)-1H-indole-3-carboxamide (compound 1017). LCMS: 99.39% ([M+H]=371.34)

[0462] 1 H NMR (400MHz, DMSO): δ11.46(br s,2H),8.01(s,1H),7.96(s,1H),7.62(s,1H),7.38-7.32(m,4H),4.71 (s,1H),3.69(s,3H),3.59(s,2H),0.89-086(m,2H),0.81-0.78(m,2H).

[0463] P. Synthesis of 6-chloro-5-(4-(1-hydroxycyclobutyl)phenyl)-N-methoxy-1H-indole-3-carboxamide (1025)

[0464]

[0465] Compound 1025 was prepared according to general synthetic route R-2 using an experimental procedure similar to that used to prepare 6-chloro-N-methoxy-5-(2-methoxy-6-(methylamino)pyridin-3-yl)-1H-indole-3-carboxamide (compound 1017).

[0466] LCMS: 97.62% ([MH] = 369.24)

[0467] 1H NMR (400MHz, DMSO): δ11.41(br s,2H),8.04(s,1H),7.97(s,1H),7.64(s,1H),7.56(d,J=8.40Hz,2H),7.41(d,J=8.00Hz,2H),5.5 3(s,1H),3.69(s,3H),2.51-2.42(m,2H),2.34-2.27(m,2H),2.00-1.92(m,1H),1.70-1.60(m,1H).

[0468] Q. Synthesis of 6-chloro-5-(6-(dimethylamino)-5-fluoro-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (1022)

[0469]

[0470] Compound 1022 was prepared according to general synthetic route R-2.

[0471]

[0472] Step 1: 5-Bromo-3,6-difluoro-N,N-dimethylpyridin-2-amine

[0473] To a stirred solution of 3,6-difluoro-N,N-dimethylpyridin-2-amine (1 g, 6.323 mmol) in ACN (10 mL) was added NBS (1.125 g, 6.323 mmol) portionwise at RT, 0°C under nitrogen atmosphere and stirred at 0°C for 30 minutes. The reaction mixture was diluted with ethyl acetate (100 mL), washed with brine (100 mL), and concentrated under reduced pressure to give 5-bromo-3,6-difluoro-N,N-dimethylpyridin-2-amine as a light yellow liquid (1.2 g; yield 80%).

[0474] Step 2: 5-Bromo-3-fluoro-6-methoxy-N,N-dimethylpyridin-2-amine

[0475] To a stirred solution of the product of step 1 (1.2 g, 0.0051 mol) in DMF (5 mL) was added NaOMe solution (25% in MeOH, 20 mL) and heated at 100° C. for 3 h. The reaction mixture was concentrated under reduced pressure, quenched with cold water, and the precipitated solid was filtered off and dried under vacuum to give crude 5-bromo-3-fluoro-6-methoxy-N,N-dimethylpyridin-2-amine (1 g; 79%).

[0476] Step 3: The product of Step 2 was coupled with 6-chloro-N-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-3-carboxamide according to the method of Example K to give 6-chloro-5-(6-(dimethylamino)-5-fluoro-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide as a white solid (35 mg; yield 9%).

[0477] LCMS : 97.14% (M+H=393.35)

[0478] 1 H NMR (400MHz, DMSO-d6): δ11.73(s,1H),11.14(s,1H),7.95(s,2H),7.57(s,1H ), 7.35 (d, J = 12.80Hz, 1H), 3.76 (s, 3H), 3.69 (s, 3H), 3.09 (d, J = 2.00Hz, 6H).

[0479] General synthetic route R-3

[0480]

[0481] Any Suzuki coupling conditions known in the art can be used to achieve the coupling of boronic acid / ester with aryl / heteroaryl halide. In an exemplary embodiment, the Suzuki coupling can be carried out in the presence of a palladium catalyst such as bis(tri-tert-butylphosphine)palladium, tetrakis(triphenylphosphine)palladium or a palladium cyclocatalyst (e.g., Bedford, RB and Cazin, CSJ (2001) Chem. Commun., 1540-1541) and a base (e.g., carbonate such as potassium carbonate).

[0482] R. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-2-methyl-1H-indole-3-carboxamide (1023)

[0483]

[0484] Compound 1023 was prepared according to general synthetic route R-3.

[0485] Step 1: 1-(5-Bromo-6-chloro-2-methyl-1H-indol-3-yl)-2,2,2-trichloroethane-1-one

[0486] To a stirred solution of 5-bromo-6-chloro-2-methyl-1H-indole (0.5 g, 2.04 mmol) in THF (10 mL) was added DMAP (25 mg, 0.20 mmol) and pyridine (0.6 mL, 7.16 mmol) at RT under nitrogen atmosphere and stirred for 10 minutes; trichloroacetyl chloride (1.2 mL, 10.22 mmol) was added dropwise and the reaction mixture was stirred at RT for 48 hours. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water, brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by flash column chromatography to give 1-(5-bromo-6-chloro-2-methyl-1H-indol-3-yl)-2,2,2-trichloroethane-1-one as a light red solid (0.55 g; 69%).

[0487] Step 2: 5-Bromo-6-chloro-N-methoxy-2-methyl-1H-indole-3-carboxamide

[0488] To a stirred solution of the product of step 1 (0.55 g, 1.41 mmol) in ACN (10 mL) was added O-methylhydroxylamine hydrochloride (0.59 g, 7.05 mmol) and TEA under nitrogen atmosphere and stirred at RT for 16 hours. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water, brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude product which was purified by flash column chromatography to give 5-bromo-6-chloro-N-methoxy-2-methyl-1H-indole-3-carboxamide as a brown solid (0.15 g; 33%).

[0489] Step 3: 6-Chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-2-methyl-1H-indole-3-carboxamide

[0490] A stirred solution of the product of step 2 (150 mg, 0.47 mmol), 6-methoxy-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (263 mg, 0.96 mmol) and K2CO3 (131 mg, 0.96 mmol) in 1,4-dioxane (4 mL) and water (1 mL) was purged with N2 for 10 minutes. PdCl2(dppf).DCM (20 mg, 0.024 mmol) was added and the reaction mixture was stirred at 80°C for 4 hours. The reaction mixture was cooled to room temperature, filtered through a celite bed, washed with EtOAc, and the combined organic materials were concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC to give 6-methoxy-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (10 mg, 5%).

[0491] LCMS: 99.06% ([M+H]=389.36)

[0492] 1 H NMR (400MHz, DMSO): δ11.63(s,1H),10.70(s,1H),7.57(s,1H),7.40(s,1H),7.32(d,J=8 .00Hz, 1H), 6.22 (d, J = 8.00Hz, 1H), 3.76 (s, 3H), 3.67 (s, 3H), 3.06 (s, 6H), 2.57 (s, 3H).

[0493] S. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-(trifluoromethyl)pyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide (1021)

[0494]

[0495] Compound 1021 was prepared according to general synthetic route R-3.

[0496] Step 1: 5-Bromo-N,N-dimethyl-6-(trifluoromethyl)pyridin-2-amine

[0497] To a stirred solution of N,N-dimethyl-6-(trifluoromethyl)pyridin-2-amine (1.9 g, 10.0 mmol) in ACN (20 mL) at 0° C. under nitrogen atmosphere was added NBS (1.7 g, 10.0 mmol) and stirred at RT for 1 hour. The solvent was evaporated under reduced pressure to give a crude product which was purified by flash column chromatography using neutral alumina to give 5-bromo-N,N-dimethyl-6-(trifluoromethyl)pyridin-2-amine as a light yellow oil (2.3 g, 83%).

[0498] Step 2: N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)pyridin-2-amine

[0499] A solution of the product of step 1 (250 mg, 268 mmol), Bis-Pin (290 mg, 1.219 mmol) and KOAc (184 mg, 1.9 mmol) in dioxane (10 mL) was purged with nitrogen for 10 minutes. Pd(OAc)2 (13 mg, 0.0466 mmol) and PCy3 (13 mg, 0.0466 mmol) were added and the reaction mixture was stirred at 90 °C for 5 hours. The reaction mixture was diluted with EtOAc, filtered through celite, and the filtrate was concentrated under reduced pressure to give crude N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)pyridin-2-amine as a light yellow gum (470 mg). This material was used in the next step without purification.

[0500] Step 3: 6-Chloro-5-(6-(dimethylamino)-2-(trifluoromethyl)pyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide

[0501] A solution of the product of step 2 (0.300 g, 0.99 mmol), 5-bromo-6-chloro-N-methoxy-1H-indole-3-carboxamide (0.470 g, 1.48 mmol) and K2CO3 (0.275 g, 1.98 mmol) in dioxane (10 mL) and water (2 mL) was purged with nitrogen for 10 minutes. PdCl2(dppf).DCM (0.40 g, 0.05 mmol) was added and the reaction mixture was stirred at 90°C for 5 hours, then diluted with EtOAc, filtered through celite and concentrated under reduced pressure to give the crude product. Purification by preparative HPLC gave 6-chloro-5-(6-(dimethylamino)-2-(trifluoromethyl)pyridin-3-yl)-N-methoxy-1H-indole-3-carboxamide as a white solid (11 mg, 12%).

[0502] LCMS:98.09%(413.34[M+H]+)

[0503] 1 H NMR 400MHz, DMSO-d6: δ11.74(br s,1H),11.18(br s,1H),7.96(m,2H),7.61(s,1H),7.48(d,J=8.80Hz,1H),6.97(d,J=8.80Hz,1H),3.69(s,3H),3.12(s,6H).

[0504] T. Synthesis of 4,6-difluoro-N-methoxy-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide (1007)

[0505]

[0506] Compound 1007 was prepared according to general synthetic route R-3.

[0507] Step 1: 5-Bromo-4,6-difluoro-N-methoxy-1H-indole-3-carboxamide

[0508] To a solution of 5-bromo-4,6-difluoro-1H-indole-3-carboxylic acid (100 mg, 0.36 mmol) in DMF (5 mL) was added HATU (207 mg, 0.54 mmol) and DIPEA (0.2 ml, 1.1 mmol). After stirring at RT for 5 minutes, NH2OMe.HCl (45 mg, 0.55 mmol) was added and the entire mixture was stirred at RT for 16 hours. The reactant was diluted with water and the product was extracted into EtOAc. After drying, the organic layer was concentrated under reduced pressure to give a crude product, which was purified by flash column chromatography to give 5-bromo-4,6-difluoro-N-methoxy-1H-indole-3-carboxamide as a white solid (70 mg).

[0509] Step 2: 4,6-difluoro-N-methoxy-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide

[0510] A solution of the product of step 1 (70 mg, 0.23 mmol), 4,4,5,5-tetramethyl-2-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1,3,2-dioxaborolane (80 mg, 0.27 mmol) and K2CO3 (80 mg, 0.5765 mmol) in dioxane (5 mL) and water (1 mL) was purged with nitrogen for 10 minutes. PdCl2(dppf).DCM (9.4 mg, 0.012 mmol) was added and stirred at 90°C for 4 hours. The reaction mixture was diluted with EtOAc, filtered through celite, and concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC to give 4,6-difluoro-N-methoxy-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide as a white solid (8 mg).

[0511] LCMS :97.78%(MH=385.44)

[0512] 1 H NMR (400MHz, DMSO-d6): δ11.10(s,1H),7.85(s,1H),7.44-7.26(m,5H),4.38(d,J=10.40H z, 1H), 4.05 (d, J = 10.40Hz, 1H), 3.66.3.56 (m, 4H), 1.88-1.86 (m, 2H), 1.65-1.47 (m, 4H).

[0513] U. Synthesis of 5-([1,1'-biphenyl]-4-yl)-6-chloro-N-methoxy-1H-indole-3-carboxamide (1008)

[0514]

[0515] Compound 1008 was prepared according to general synthetic route R-3.

[0516] To a stirred solution of 5-bromo-6-chloro-N-methoxy-1H-indole-3-carboxamide (200 mg, 0.65 mmol) in 1,4-dioxane (10 mL) and water (2 mL) was added [1,1'-biphenyl]-4-ylboronic acid (0.16 g, 0.79 mmol) and K2CO3 (0.27 g, 1.98 mmol). The reaction mixture was purged with N2, then PdCl2(dPPf)2.DCM (0.4 g, 0.652 mmol) was added, and the reaction mixture was heated at 90°C for 5 hours. The reaction mixture was cooled to 25°C, filtered through a celite bed and concentrated under reduced pressure to give a crude product, which was purified by preparative HPLC to give 5-([1,1'-biphenyl]-4-yl)-6-chloro-N-methoxy-1H-indole-3-carboxamide as a white solid (15 mg, 6.1%).

[0517] LCMS: 97.20% (377.14, M+H);

[0518] 1 H NMR 400MHz, DMSO-d6: δ11.48(br s,2H),8.10(s,1H),7.99(s,1H),7.78-7.74(m,4H),7.66(s,1H),7.55-7.48(m,4H),7.42-7.37(m,1H),3.71(s,3H).

[0519] T. Synthesis of 4,6-difluoro-N-methoxy-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide (1078)

[0520]

[0521] Compound 1078 was prepared according to general synthetic route R-3.

[0522] To a solution of 4,6-difluoro-N-((tetrahydro-2H-pyran-2-yl)oxy)-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide (see Example J) (70 mg, 0.15 mmol) in MeOH (5 mL) was added pTSA (5.2 mg, 0.03 mmol) and stirred at RT for 1 hour. The reaction mixture was concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC to give 4,6-difluoro-N-hydroxy-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide as a white solid (8 mg, 13% yield).

[0523] LCMS: 98.53% (M+H=373.31)

[0524] 1 H NMR (400MHz, DMSO-d6): δ11.12(br, 1H),8.85(br s,1H),7.76(s,1H),7.44-7.38(m,4H),7.23(d,J=10.00Hz,1H),4.39(d,J=1.60Hz,1 H), 4.05 (d, J = 10.80Hz, 1H), 3.59-3.54 (m, 1H), 1.87-1.84 (m, 2H), 1.59-1.53 ​​(m, 4H).

[0525] B. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-hydroxy-1H-indole-3-carboxamide (1001)

[0526]

[0527] Compound 1001 was prepared according to general synthetic route R-3 using an experimental procedure similar to that used to prepare 4,6-difluoro-N-hydroxy-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide (1078).

[0528] LCMS :95.20%(361.22[M+H]+)

[0529] 1 H NMR; 400MHz, DMSO-d6: δ11.55-10.71(br,2H),8.75(s,1H),7.94(s,1H),7.89(s,1H), 7.53 (s, 1H), 7.31 (d, J = 8.4Hz, 1H), 6.21 (d, J = 8.00Hz, 1H), 3.76 (s, 3H), 3.07 (s, 6H).

[0530] U. Synthesis of 5-([1,1'-biphenyl]-4-yl)-6-chloro-N-hydroxy-1H-indole-3-carboxamide (1006)

[0531]

[0532] Compound 1006 was prepared according to general synthetic route R-3 using an experimental procedure similar to that used to prepare 4,6-difluoro-N-hydroxy-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide (1078).

[0533] LCMS:99.04%(361.10[MH]-)

[0534] 1 H NMR 400MHz, DMSO-d6: δ11.69(br s,1H),10.69(br s,1H),8.79(s,1H),8.11(s,1H),7.97(s,1H),7.77-7.73(m,4H),7.65(s,1H),7.55-7.48(m,4H),7.39(t,J=7.2Hz,1H).

[0535] Structural unit

[0536] Example A1 Synthesis of 3-bromo-6-(4,4-difluoropiperidin-1-yl)-2-methoxypyridine

[0537] (for 1058)

[0538]

[0539] A mixture of 2,6-difluoropyridine (1.0 g, 0.87 mmol), K2CO3 (3.59 g, 0.0260 mol) and 4,4-difluoropiperidine hydrochloride in acetonitrile (25 mL) was heated to 80 °C for 3 h. The reaction was cooled to RT, the solid material was filtered off, and the filtrate was concentrated under reduced pressure to give 3 as a light yellow thick gum (1 g, 53%). This material was dissolved in DMF (2.5 mL) and reacted with NaOMe (25% in MeOH) (10 mL) at 100 °C for 3 h. The product was isolated by a water / ether extraction procedure to give 4 as a light yellow liquid (1 g). The substance was dissolved in acetonitrile (50 mL) and reacted with NBS (313 mg, 0.0018 mol) at -10°C under nitrogen atmosphere for 30 minutes. The reaction mixture was concentrated under reduced pressure and the product was separated by water / ether extraction procedure and then subjected to column chromatography to obtain 3-bromo-6-(4,4-difluoropiperidin-1-yl)-2-methoxypyridine (5) as a light yellow liquid (0.5 g). LCMS (M+H=307.18).

[0540] The following intermediates were prepared in a similar manner:

[0541] 5-Bromo-N-(cyclobutylmethyl)-6-methoxy-N-methylpyridin-2-amine for 1054

[0542]

[0543] 4-(5-bromo-6-methoxypyridin-2-yl)-1,4-oxazepane, LCMS: (M+H=287.24), used for 1059

[0544]

[0545] N1-(5-bromo-6-methoxypyridin-2-yl)-N1,N2,N2-trimethylethane-1,2-diamine, used in 1063

[0546]

[0547] N1-(5-bromo-6-methoxypyridin-2-yl)-N1,N3,N3-trimethylpropane-1,3-diamine, used for 1064; LCMS: 302.27 (M+H)

[0548]

[0549] tert-Butyl 4-(5-bromo-6-methoxypyridin-2-yl)piperazine-1-carboxylate, used for 1095; LCMS: 88% (M+H=372.15)

[0550]

[0551] 5-Bromo-4-methoxy-N,N-dimethylpyrimidin-2-amine, used for 1046; LCMS: ([M+H]=232.01)

[0552]

[0553] 5-Bromo-6-methoxy-N-methyl-N-(tetrahydro-2H-pyran-4-yl)pyridin-2-amine, used for 1057; LCMS: ([M+H]=301.17)

[0554]

[0555] Example A2. Synthesis of 4-(5-bromo-6-methoxypyridin-2-yl)morpholine (for synthesis of 1034)

[0556]

[0557] To a solution of 4-(6-fluoropyridin-2-yl)morpholine (2.0 gm, 10.98 mmol) prepared as in Example A1 above using morpholine in ACN at 0°C under nitrogen was added NBS (1.95 gm, 10.98 mmol). After 1 hour at RT, the product was isolated by aqueous organic workup and purified by flash column chromatography to give 4-(5-bromo-6-fluoropyridin-2-yl)morpholine (1.7 g, 83% yield) as a yellow liquid, LCMS: (269.40 (M+H)). This material was reacted with NaOMe in DMF (5 mL) at 90°C for 3 hours to give 4-(5-bromo-6-methoxypyridin-2-yl)morpholine (0.8 g) as a light yellow gum, LCMS: (316.28) (M+H).

[0558] The following intermediates were prepared in a similar manner:

[0559] 1-(5-Bromo-6-methoxypyridin-2-yl)-4-methylpiperazine, used for 1048; LCMS: (286.05 (M+H))

[0560]

[0561] 3-Bromo-2-methoxy-6-(4-methylpiperidin-1-yl)pyridine, used for 1049; LCMS: (285.13 (M+H))

[0562]

[0563] 2-(5-Bromo-6-methoxypyridin-2-yl)-2-azaspiro[3.3]heptane, used for 1050; LCMS: (285.13, M+H)

[0564]

[0565] 5-Bromo-6-methoxy-N-(2-methoxyethyl)-N-methylpyridin-2-amine, used for 1051; LCMS: (275.13 [M+H] + )

[0566]

[0567] 5-Bromo-N-(2-isopropoxyethyl)-6-methoxy-N-methylpyridin-2-amine, used for 1052; LCMS: (301.13, M+H)

[0568]

[0569] 5-Bromo-N-butyl-N-ethyl-6-methoxypyridin-2-amine for 1056

[0570]

[0571] 3-Bromo-2-methoxy-6-(4-methoxypiperidin-1-yl)pyridine, used for 1055; LCMS: (301.13, M+H)

[0572]

[0573] Example B.1-(5-bromopyridin-2-yl)cyclopropyl)methanol for the synthesis of 1101

[0574]

[0575] A mixture of 2-(5-bromopyridin-2-yl)acetonitrile (2 g, 10.2 mmol), 1,2-dibromoethane (1.74 g, 20.3 mmol), benzyltriethylammonium chloride (BTEAC, 254 mg, 1.116 mmol) in 50% aqueous NaOH solution (20 mL) was heated at 75 °C for 3 hours. After aqueous organic workup, purification by flash chromatography gave 1-(5-bromopyridin-2-yl)cyclopropane-1-carbonitrile (1.8 g, 79.6% yield) as a light brown solid. LCMS: (M+2=225.12). The product was treated with NaOH (1.93 g, 48.415 mmol) in MeOH:H2O (18 mL:18 mL) at 90°C for 16 h to give 1-(5-bromopyridin-2-yl)cyclopropane-1-carboxylic acid (1.6 g, 82.05%) as an off-white solid; LCMS: 95.93% (M+2=244.06). The product was reduced with BH3 (23 mL, 23.54 mmol, 1 M in DMS) in THF (16 mL) at -78°C and then kept at RT for 16 h to give (1-(5-bromopyridin-2-yl)cyclopropyl)methanol (0.9 g; 60% yield) as a white solid.

[0576] LCMS: 79.97% (M+H=228.15)

[0577] 1 H NMR 400MHz, DMSO-d6: δ8.52(s,1H),7.92(dd,J=2.40,8.40Hz,1H),7.49(d,J=8.80Hz,1H),4.8 0 (t, J = 5.60 Hz, 1H), 3.72 (d, J = 5.20 Hz, 2H), 1.08 (d, J = 2.40 Hz, 2H), 0.92 (t, J = 2.40 Hz, 2H).

[0578] Example C. Synthesis of 1-(5-bromopyridin-2-yl)cyclobutan-1-ol (for the synthesis of 1099)

[0579]

[0580] n-BuLi (4 mL, 0.0247) was slowly added to a stirred solution of 5-bromo-2-iodopyridine (3.0 g, 0.026 mmol) in DCM (30 mL) at -78 °C. After 45 min, cyclobutanone (2.99 g, 0.052 mmol) was added and the reaction was stirred at -78 °C for 2 h. The reaction was quenched with NH4Cl solution (50 mL) to give 1-(5-bromopyridin-2-yl)cyclobutan-1-ol (0.9 g) as a brown gum after aqueous organic work-up and flash chromatography purification.

[0581] LCMS: 83% (228, M+H)

[0582] 1 H NMR 400MHz, CDCl3: δ8.66(d,J=2.40Hz,1H),7.99(dd,J=2.40,8.40Hz,1H),7.52(d,J=8.40Hz,1 H),5.82(s,1H),2.50-0.00(m,2H),2.18-2.25(m,2H),1.82-1.87(m,1H),1.89-1.92(m,1H).

[0583] Example D. Synthesis of 3-bromo-2-methoxy-6-((trimethylsilyl)ethynyl)pyridine (for the synthesis of 1093)

[0584]

[0585]

[0586] NBS (14.27 g, 80.64 mmol) in DMF (20 mL) was added dropwise to a solution of 2-methoxypyridin-3-amine (10.0 g, 80.64 mmol) in DMF (60 mL) at 0 °C and then stirred at RT for 16 h. After aqueous organic work-up and purification by flash column chromatography, 2-methoxypyridin-3-amine (8.5 g, 52% yield) was obtained as a brown solid (LCMS: ([M+H] = 205). A solution of this product (8 g, 39.40 mmol) and TMS acetylene (11.5 g, 118.2 mmol) in TEA (70 mL) was purged with nitrogen. CuI (748 mg, 0.003 mmol) and PdCl2(PPh3) (1.3 g, 1.97 mmol) were added and the reaction mixture was stirred at RT for 48 h. After aqueous organic work-up and purification by flash column chromatography , 2-methoxy-6-((trimethylsilyl)ethynyl)pyridine-3-amine (7.5 g, 86% yield) was obtained as a brown solid LCMS: ([M+H]=221). At 0°C, a solution of the product (2 g, 43.10 mmol) in acetonitrile (20 mL) was treated dropwise with tert-butyl nitrite (4 g) and then with CuBr2 (4 g). The reaction mixture was stirred at RT for 16 hours, evaporated under reduced pressure, and the crude product was purified by flash column chromatography to give 3-bromo-2-methoxy-6-((trimethylsilyl)ethynyl)pyridine (1.8 g, 70% yield) as an orange liquid.

[0587] LCMS: (M+H]=284).

[0588] Example E. Synthesis of 4-(5-bromo-6-methoxypyridin-2-yl)-2-methylbut-3-yn-2-ol (for the synthesis of 1093)

[0589]

[0590] A solution of 6-bromo-2-methoxypyridin-3-amine (2.5 g, 12.31 mmol), 2-methylbut-3-yn-2-ol (2.07 g, 24.62 mmol) and piperidine (3.71 g, 43.7 mmol) in THF (10 mL) was purged with nitrogen for 5 minutes. Pd(PPh3)4 (32 mg, 0.027 mmol) and PPh3 (12 mg, 0.046 mmol) were added. Purging was continued, and then CuBr (12 mg, 0.086 mmol) and LiI (66 mg, 0.492 mmol) were added. After 16 hours at 90° C., the reaction mixture was dried under reduced pressure and the crude product was purified by flash column to give 4-(5-amino-6-methoxypyridin-2-yl)-2-methylbut-3-yn-2-ol (1.8 g, 72% yield) as an orange solid LCMS: ([M+H]=207.32). As described in Example D, the product was reacted with tert-butyl nitrite (3.6 g) and CuBr2 (3.6 g) in acetonitrile (18 mL) at RT for 18 hours to give 4-(5-bromo-6-methoxypyridin-2-yl)-2-methylbut-3-yn-2-ol (0.8 g, 34% yield) as an off-white solid.

[0591] LCMS: ([M+H]=270.09).

[0592] Synthesis of Compounds of the Disclosure

[0593] Example 1. Synthesis of 2-(4,6-difluoro-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indol-3-yl)-2-oxoacetic acid (1096)

[0594]

[0595] A solution of 5-bromo-4,6-difluoro-1H-indole (100 mg, 0.43 mmol), 4,4,5,5-tetramethyl-2-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1,3,2-dioxaborolane (148 mg, 0.51 mmol) and K2CO3 (118 mg, 0.86 mmol) in 1,4-dioxane (10 mL) and water (2 mL) was purged with nitrogen for 10 minutes. PdCl2(dppf).DCM (17.5 mg, 0.021 mmol) was added and the reaction mixture was stirred at 90°C. After 16 h, the reaction mixture was filtered through a bed of celite, concentrated under reduced pressure, and purified by flash column chromatography to give 4,6-difluoro-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole (60 mg, 44% yield) as an off-white solid; LCMS: 67.50% ([MH] = 312.24). The product was dissolved in ether (10 mL) at 0 °C, oxalyl chloride (0.2 mL, 0.9 mmol) was added, and the mixture was stirred at RT for 5 h. Evaporated to dryness to give 2-(4,6-difluoro-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indol-3-yl)-2-oxoacetic acid (50 mg) as a yellow solid.

[0596] LCMS: ([M+H]=386.29).

[0597] Example 2. Synthesis of N-(butylsulfonyl)-6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indole-3-carboxamide (1108)

[0598]

[0599] Potassium tert-butoxide (268 mg, 2.4 mmol) was slowly added to a stirred solution of 1-(5-bromo-6-chloro-1H-indol-3-yl)-2,2,2-trichloroethane-1-one (300 mg, 0.6 mmol) in DMF (5 mL) at 0°C. N-Butylsulfonamide (219 mg, 1.6 mmol) was added and the reaction was heated in a microwave reactor at 120°C for 3 hours. The reaction mixture was cooled, filtered through celite, evaporated to dryness, and purified by reverse phase chromatography to give 5-bromo-N-(butylsulfonyl)-6-chloro-1H-indole-3-carboxamide (100 mg, 32% yield) as a light yellow liquid (LCMS: (M+H=393.26)). The product was mixed with 6-methoxy-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (283 mg, 1 mmol; 30% pure) and K2CO3 (247 mg, 1.7895 mmol) in dioxane (10 mL) and water (1 mL) and purged with nitrogen for 10 minutes. PdCl2(dppf).DCM (28 mg, 0.03479 mmol) was added and the reaction mixture was heated to 90°C for 5 hours. The reaction mixture was cooled, filtered through celite, evaporated to dryness, and purified by reverse phase chromatography to give N-(butylsulfonyl)-6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indole-3-carboxamide (5 mg; 4% yield) as a white solid.

[0600] LCMS: (M+H=465.34)

[0601] 1 H NMR 400MHz, CDCl3: δ11.19(s,1H),8.12(s,1H),7.66(s,1H),7.40(s,1H),7.28(d,J=8.00Hz,1H),6.20(d,J= 8.40Hz,1H),3.76(s,3H),3.06-3.01(m,8H),1.57-1.53(m,2H),1.33-1.24(m,3H),0.83(t,J=7.6Hz,3H).

[0602] Example 3. Synthesis of 4,6-difluoro-N-(2-methoxyethoxy)-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide (1042)

[0603]

[0604] To a solution of 5-bromo-4,6-difluoro-1H-indole-3-carboxylic acid (250 mg, 0.90 mmol) in DMF (5 mL) was added HATU (516 mg, 1.35 mmol), DIPEA (0.5 ml, 2.1 mmol) and stirred for 5 minutes; O-(2-methoxyethyl)hydroxylamine (124 mg, 1.35 mmol) was added and stirred at room temperature for 2 hours. The product was isolated by aqueous organic workup followed by flash column chromatography to give 5-bromo-4,6-difluoro-N-(2-methoxyethoxy)-1H-indole-3-carboxamide (80 mg, yield 25%) as a white solid, LCMS: (349.26 [M+H] + ). The product was mixed with (4-(tetrahydro-2H-pyran-2-yl)phenyl)boronic acid (66.2 mg, 0.2298 mmol) and K2CO3 (80 mg, 0.57 mmol) in dioxane:water (4 mL:1 mL) and purged with nitrogen for 10 minutes; PdCl2(dppf).DCM (9.38 mg, 0.0114 mmol) was added and the reaction was heated at 90°C for 4 hours. Filtration through celite, evaporation and purification by preparative HPLC gave 4,6-difluoro-N-(2-methoxyethoxy)-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-carboxamide (12 mg) as an off-white solid.

[0605] 1 H NMR (400MHz, DMSO-d6): δ12.12(s,1H),11.01(s,1H),7.84(s,1H),7.44-7.38(m,4H),7.24(d,J=10.00Hz,1H),4.39(d,J=1.60 Hz,1H),4.05(d,J=11.60Hz,1H),3.99(t,J=4.40Hz,2H),3.59-3.53(m,3H),3.28(s,3H),1.88-1.85(m,2H),1.70-1.49(m,4H).

[0606] LCMS: 99.66% (429.53 [MH] + ).

[0607] Example 4. Synthesis of 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-sulfonamide (1070)

[0608]

[0609] Step 1: 5-Bromo-6-chloro-1H-indole-3-sulfonyl chloride

[0610] Chlorosulfonic acid (4 mL) was added dropwise to a solution of 5-bromo-6-chloro-1H-indole (2.0 g, 8.68 mmol) in acetonitrile at 0° C. After 2 h at RT, the reaction mixture was diluted with ice water (and the precipitated solid was filtered, washed with water, and dried under vacuum to give 5-bromo-6-chloro-1H-indole-3-sulfonyl chloride as an off-white solid (1.7 g, 59% yield. LCMS: ([MH]=325.91).

[0611] Step 2: 6-Chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-sulfonamide

[0612] A solution of the product of step 1 (1.5 g, 4.56 mmol) in DMF (15 mL) was cooled to 0°C. K2CO3 (2.52 g, 18.24 mmol) and methoxyamine hydrochloride (0.762 g, 9.12 mmol) were added at 0°C and the reaction mixture was stirred at RT. After 2 hours, the mixture was diluted with ice water (200 mL), the precipitated solid was filtered, washed with water, and dried under vacuum to give 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-sulfonamide (0.5 g, 32% yield) as an off-white solid.

[0613] 1 H NMR (400MHz, DMSO-d6): δ12.41 (s, 1H), 10.24 (s, 1H), 8.10 (d, J = 4.00Hz, 2H), 7.80 (s, 1H), 3.66 (s, 3H). LCMS: ([MH]=336.99).

[0614] Step 3: 6-Chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-sulfonamide

[0615] A stirred solution of the product of step 2 (100 mg, 0.3 mmol), 6-methoxy-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (126 mg, 0.45 mmol) and K2CO3 (83 mg, 0.6 mmol) in 1,4-dioxane (1.8 mL) and water (0.2 mL) was purged with nitrogen for 10 minutes. PdCl2(dppf).DCM (13 mg, 0.015 mmol) was added and the reaction mixture was stirred at 100°C. After 16 hours, it was cooled, filtered through celite, concentrated under reduced pressure, and purified by flash column chromatography to give 6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-N-methoxy-1H-indole-3-sulfonamide (25 mg, 20% yield).

[0616] 1 H NMR (400MHz, DMSO-d6): δ12.20(s,1H),10.14(s,1H),8.03(s,1H),7.65(s,1H),7.61(s,1H),7.32(d, J=8.00Hz, 1H), 6.23 (d, J=8.40Hz, 1H), 3.77 (s, 3H), 3.63 (s, 3H), 3.07 (s, 6H); LCMS: ([M+H]=411.25).

[0617] The following compounds were prepared in a similar manner:

[0618] 5-([1,1'-Biphenyl]-4-yl)-6-chloro-N-methoxy-1H-indole-3-sulfonamide (1110)

[0619]

[0620] 1 H NMR (400MHz, DMSO-d6): δ12.32(s,1H),10.20(s,1H),8.10(s,1H),7.73-7.82(m ,6H),7.49-7.57(m,4H),7.38-7.42(m,1H),3.65(s,3H); LCMS: ([MH]=411.18).

[0621] 6-Chloro-N-methoxy-5-(4-(tetrahydro-2H-pyran-2-yl)phenyl)-1H-indole-3-sulfonamide (1109)

[0622]

[0623] 1H NMR (400MHz, DMSO-d6): δ12.32(s,1H),10.20(s,1H),8.00(s,1H),7.71(s,1H),7.64(s,1H),7.38-7.42(m,4H),4.37(dd,J= 1.60, 11.00Hz, 1H), 4.05 (d, J = 10.80Hz, 1H), 3.53-3.61 (m, 4H), 1.84-1.90 (m, 2H), 1.53-1.70 (m, 4H); LCMS: ([MH] = 419.20).

[0624] Example 5. Synthesis of 2-(6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indol-3-yl)-2-oxoacetic acid (1113)

[0625]

[0626] Oxalyl chloride (0.28 ml, 3.31 mmol) was added dropwise to a solution of 5-(6-chloro-1H-indol-5-yl)-6-methoxy-N,N-dimethylpyridin-2-amine (200 mg, 0.66 mmol) in diethyl ether (2 mL) at 0° C. After stirring at RT for 0.5 h, the reaction mixture was filtered and dried under vacuum, and the crude product was purified by preparative HPLC to give 2-(6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indol-3-yl)-2-oxoacetic acid (15 mg, 6% yield) as a light yellow solid.

[0627] LCMS: 97.23% (374.20 [M+H] - ).

[0628] 1 H NMR (400MHz, DMSO-d6): δ13.30(br s,1H),11.78(s,1H),8.13(s,1H),8.00(s,1H),7.54(s,1H),7.30(d,J=8.00Hz,1H),6.22(d,J=8.00Hz,1H),3.76(s,3H),3.07(s,6H).

[0629] Example 6. Synthesis of 2-(6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indol-3-yl)-N-methoxy-2-oxoacetamide (1083)

[0630]

[0631] To a solution of 2-(6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indol-3-yl)-2-oxoacetic acid (400 mg, 1.0701 mmol)) in DMF (5 mL) was added HATU (610 mg, 1.6 mmol) and DIPEA (0.6 mL, 3.2 mmol) at room temperature and the reaction was stirred for 15 minutes. HCl.NH2OMe (134 mg, 1.6 mmol) was then added and the reaction was stirred at room temperature for 16 hours. After aqueous organic workup, the crude product was purified by preparative HPLC to give 2-(6-chloro-5-(6-(dimethylamino)-2-methoxypyridin-3-yl)-1H-indol-3-yl)-N-methoxy-2-oxoacetamide (20 mg, 5% yield) as a yellow solid.

[0632] LCMS: 92.53% (403.32 [M+H] - ).

[0633] HPLC: 91.95%

[0634] 1 H NMR (400MHz, DMSO-d6): δ12.33(s,1H),12.03(s,1H),8.70(s,1H),8.03(s,1H),7.65(s,1 H), 7.33 (d, J = 8.40Hz, 1H), 6.23 (d, J = 8.40Hz, 1H), 3.76 (s, 3H), 3.70 (s, 3H), 3.07 (s, 6H).

[0635] Example 2: EC 50 data

[0636] The EC of the disclosed compounds was determined 50 The data are shown in Table A below.

[0637] Table A: EC 50 Data (showing compound numbers)

[0638]

[0639]

[0640] Example 3: Blood-brain barrier data

[0641] Blood-brain barrier (BBB) ​​data were evaluated for compounds of the present disclosure and the values ​​are shown in Table B. Brain / plasma ratios were calculated at the 3 hour time point.

[0642] Table B: BBB data (showing compound numbers)

[0643]

[0644]

[0645] Example 4: Spectral Data of the Disclosed Compounds

[0646] Table C below shows the NMR and LCMS data for the compounds of the present disclosure: Table C: Spectral Data

[0647]

[0648]

[0649]

[0650]

[0651]

[0652]

[0653]

[0654]

[0655]

[0656]

[0657]

[0658] A number of patents and non-patent publications are cited herein to describe the state of the art to which the present disclosure relates. The entire disclosures of these publications are incorporated herein by reference.

[0659] Although certain embodiments of the present disclosure have been described and / or illustrated above, various other embodiments will be apparent to those skilled in the art based on the foregoing disclosure. Therefore, the present disclosure is not limited to the specific embodiments described and / or illustrated, but can be considerably changed and modified without departing from the scope and spirit of the appended claims.

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof: Wherein in formula (I): X1 for CR 4a or N; X2 for CR 4b or N; R1 is selected from R2 is selected from H, C 1-3 Alkyl, -CF3 and halide; R3 at each occurrence is independently selected from halo, -CN, -N(R 10 2. C 1-10 Alkyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Cycloalkyloxy, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 Heterocycloalkenylalkyl, aryl and heteroaryl, wherein C 1-10 Alkyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 The heterocycloalkenyl alkyl, aryl or heteroaryl groups are unsubstituted or substituted with one to three radicals selected from deuterium, halo, C 1-6 Alkyl, C 3-6 Substitution by substituents of cycloalkyl, -OR5 and -OCOR7; R 4a is independently selected at each occurrence from H, halo, C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl and C 4-10 Cycloalkylalkyl, wherein C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl or C 4-10 Cycloalkylalkyl is unsubstituted or substituted with one to three halogen substituents; R 4b independently selected at each occurrence from H, C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl and C 4-10 Cycloalkylalkyl, wherein C 1-10 Alkyl, C 3-7 Cycloalkyl, C 3-10 Heterocyclic group, C 4-12 Alkylcycloalkyl or C 4-10 Cycloalkylalkyl is unsubstituted or substituted with one to three halogen substituents; R5 at each occurrence is independently selected from H, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl and C 4-10 Cycloalkylalkyl, wherein C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl or C 4-10 Cycloalkylalkyl is unsubstituted or substituted with one to three halogen substituents; R6 at each occurrence is independently selected from H, C 1-6 Alkyl and C 3-6 Cycloalkyl; R7 is independently selected at each occurrence from C 1-10 Alkyl, C 3-7 Cycloalkyl and C 4-12 Alkylcycloalkyl, wherein C 1-10 Alkyl, C 3-7 Cycloalkyl or C 4-12 Alkylcycloalkyl is unsubstituted or substituted by one to three groups selected from halogen, C 1-10 Alkyl and -NR 12 , R 12 Substituents are substituted; R8 is selected from H, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-10 Heterocyclic group, C 4-12 Alkyl heterocyclic group, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 Heterocycloalkenylalkyl, aryl, heteroaryl, Among them C 1-10 Alkyl, C 1-10 Alkoxy, C 3-7 Cycloalkyl, C 4-12 Alkylcycloalkyl, C 4-10 Cycloalkylalkyl, C 3-10 Heterocyclic group, C 4-12 Alkyl heterocyclic group, C 3-7 Heterocycloalkenyl, C 4-12 Alkyl heterocycloalkenyl, C 4-10 Heterocycloalkenylalkyl, aryl or heteroaryl is unsubstituted or substituted with one to three substituents selected from deuterium, halo and -OR5; R 10 independently selected at each occurrence from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 4-12 Alkylcycloalkyl, and C 3-10 Heterocyclic group, wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, C 4-12 Alkylcycloalkyl or C 3-10 The heterocyclic group is unsubstituted or substituted by one to three radicals selected from deuterium, halogen, C 1-6 Alkyl and C 3-6 Substitution of cycloalkyl groups; R 11 In each occurrence, independently selected from -OR 12 and -N(R 12 )2; R 12 independently selected at each occurrence from H, C 1-6 Alkyl, C 1-10 Haloalkoxy and C 3-6 Cycloalkyl; n is an integer from 0 to 3; p is an integer from 1 to 5; q is an integer from 0 to 5; r is an integer from 1 to 5; s is an integer from 1 to 5; A is selected from phenyl, pyridyl, pyrimidinyl, pyridazinyl and the following 5-membered heterocyclic rings: The premise is that the compound of formula (I) is not 2. The compound as claimed in claim 1, wherein X1 is CR 4a .

3. The compound as claimed in claim 2, wherein R 4a is H, Cl or F.

4. The compound according to any one of claims 1 to 3, wherein X2 is N or CR 4b , where R 4b For H.

5. The compound of any one of claims 1 to 4, wherein R2 is halogen.

6. The compound of claim 5, wherein R2 is Cl or F.

7. A compound as described in any one of claims 1 to 6, wherein R6 is H.

8. The compound of any one of claims 1 to 7, wherein A is selected from:

9. The compound according to any one of claims 1 to 8, wherein the compound of formula (I) is a compound of formula (10), formula (11), formula (12), formula (13), formula (14), formula (15), formula (16) or formula (17), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

10. A compound as described in any one of claims 1 to 9, wherein R1 is 11. The compound of claim 10, wherein the compound of formula (I) is a compound of formula (100), formula (110), formula (120), formula (130), formula (140), formula (150), formula (160) or formula (170), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

12. A compound as described in any one of claims 1 to 9, wherein R1 is 13. The compound of claim 12, wherein the compound of formula (I) is a compound of formula (200), formula (210), formula (220), formula (230), formula (240), formula (250), formula (260) or formula (270), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

14. A compound as described in any one of claims 1 to 9, wherein R1 is 15. The compound of claim 14, wherein the compound of formula (I) is a compound of formula (300), formula (310), formula (320), formula (330), formula (340), formula (350), formula (360) or formula (370), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

16. The compound of claim 14 or 15, wherein the compound is selected from:

17. A compound as described in any one of claims 1 to 9, wherein R1 is 18. The compound of claim 17, wherein the compound of formula (I) is a compound of formula (400), formula (410), formula (420), formula (430), formula (440), formula (450), formula (460) or formula (470), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

19. A compound as described in any one of claims 1 to 9, wherein R1 is 20. The compound of claim 19, wherein the compound of formula (I) is a compound of formula (500), formula (510), formula (520), formula (530), formula (540), formula (550), formula (560) or formula (570), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

21. A compound as described in any one of claims 1 to 9, wherein R1 is 22. The compound of claim 21, wherein the compound of formula (I) is a compound of formula (600), formula (610), formula (620), formula (630), formula (640), formula (650), formula (660) or formula (670), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

23. A compound as described in any one of claims 1 to 9, wherein R1 is 24. The compound of claim 23, wherein the compound of formula (I) is a compound of formula (700), formula (710), formula (720), formula (730), formula (740), formula (750), formula (760) or formula (770), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

25. A compound as described in any one of claims 1 to 9, wherein R1 is 26. The compound of claim 25, wherein the compound of formula (I) is a compound of formula (800), formula (810), formula (820), formula (830), formula (840), formula (850), formula (860) or formula (870), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

27. A compound as described in any one of claims 1 to 9, wherein R1 is 28. The compound of claim 27, wherein the compound of formula (I) is a compound of formula (900), formula (910), formula (920), formula (930), formula (940), formula (950), formula (960) or formula (970), or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

29. A compound as described in any one of claims 1 to 28, wherein R 10 Selected from H, methyl, ethyl, -CD3, n-butyl, 30. A compound as described in any one of claims 1 to 29, wherein R 11 Selected from 31. The compound of any one of claims 1-30, wherein p is 2 or 3.

32. A compound as described in any one of claims 1-31, wherein R3 is selected from -F, -CN, ethyl, Optionally selected from 33. A compound as described in any one of claims 1-32, wherein R3 is selected from Optionally selected from 34. A compound as described in any one of claims 1-33, wherein q is 0 or 1.

35. The compound of any one of claims 1-33, wherein r is 2 or 3.

36. The compound of any one of claims 1-33, wherein s is 1.

37. A compound as described in any one of claims 1 to 36, wherein R 12 Selected from methyl, ethyl, -OCF3 and 38. A compound as described in any one of claims 1-37, wherein R8 is selected from H, methyl, ethyl, isopropyl, n-butyl, tert-butyl, 39. A compound as described in any one of claims 1-38, wherein R8 is selected from H, methyl, ethyl, n-butyl, 40. A compound as described in any one of claims 1-39, wherein R8 is selected from H, methyl and ethyl.

41. The compound of claim 1, wherein the compound of formula (I) is selected from a compound having a formula selected from formula 1001-1114, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof:

42. The compound of claim 1, wherein the compound of formula (I) is selected from: or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof.

43. The compound of claim 1, wherein the compound of formula (I) is selected from: or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof.

44. The compound of claim 1, wherein the compound of formula (I) is selected from: or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal or prodrug thereof.

45. The compound of claim 1, wherein when A is a 5-membered heterocyclic ring and R1 is When R8 is not H.

46. ​​A pharmaceutical formulation comprising a compound according to any one of claims 1-45.

47. A method of treating a patient suffering from mitochondrial dysfunction, comprising: Identify mitochondrial dysfunction in individuals; and The patient is administered a compound according to any one of claims 1-44.

48. A method of treating a patient suffering from mitochondrial dysfunction comprising administering to the patient a therapeutically effective amount of a compound of any one of claims 1-45.

49. The method of claim 47 or 48, wherein the mitochondrial dysfunction is primary mitochondrial dysfunction.

50. The method of claim 49, wherein the primary mitochondrial dysfunction is selected from the group consisting of: autosomal dominant optic atrophy (ADOA), Alpers-Huttenlocher syndrome (nDNA defect), ataxic neuropathy syndrome (nDNA defect), Barth syndrome / lethal infantile cardiomyopathy (LIC), coenzyme Q deficiency, complex I, complex II, complex III, complex IV and complex V deficiency (single or any combination of deficiencies), chronic progressive external ophthalmoplegia (CPEO), diabetes and deafness, Kearns-Sayre syndrome (mtDNA defect), leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate (LBSL-leukodystrophy), Leigh syndrome (mtDNA and nDNA defects), Leber hereditary optic neuropathy (LHON), Luft disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke syndrome (MELAS) (mtDNA defect), mitochondrial enoyl-CoA reductase protein-associated neurodegeneration (MEPAN), myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial recessive ataxia syndrome (MIRAS), mtDNA deletion syndrome, mtDNA depletion syndrome, mtDNA maintenance disorder, mtDNA / RNA translation defect, mitochondrial tRNA synthetase defect, mitochondrial myopathy, mitochondrial neurogastroenteric encephalopathy syndrome (MNGIE), neurogenic myasthenia, ataxia, and retinitis pigmentosa (NARP), Pearson syndrome, pyruvate dehydrogenase complex deficiency (PDCD / PDH), DNA polymerase gamma deficiency (POLG), pyruvate carboxylase deficiency, and thymidine kinase 2 deficiency (TK2).

51. The method of claim 47 or 48, wherein the mitochondrial dysfunction is secondary mitochondrial dysfunction.

52. The method of claim 51, wherein the secondary mitochondrial dysfunction is selected from the group consisting of: age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and other dementias, Friedreich's ataxia (FA), Huntington's disease (HD), motor neuron disease (MND), N-glycanase deficiency (NGLY1), organic acidemias, Parkinson's disease (PD) and PD-related disorders, prion diseases, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA), Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, Muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, Charcot-Marie-Tooth disease, congenital myopathies, distal myopathies, endocrine myopathies (hyperthyroid myopathy, hypothyroid myopathy), giant axonal neuropathy, hereditary spastic paraplegia, inflammatory myopathies (dermatomyositis, inclusion body myositis, polymyositis), metabolic myopathies, neuromuscular junction disorders, autism, cancer, diabetes, metabolic syndrome, chronic fatigue syndrome, inflammatory disorders, arthritis, aging, and mitochondrial epilepsy (epilepsy secondary to primary mitochondrial disease).

53. The method of claim 47 or 48, wherein the compound is administered in the form of a pharmaceutical formulation.

54. The method of claim 53, wherein the pharmaceutical formulation comprises the compound and at least one selected from a binder, a lubricant, a buffer, and a coating.

55. The method of claim 47 or 48, wherein the compound is administered orally.

56. The method of claim 47 or 48, wherein the compound is administered daily for at least one week.

57. The method of claim 47, further comprising evaluating the efficacy of the compound in the individual.

58. The method of claim 47 or 48, wherein the compound is administered orally, subcutaneously, intravenously, intraperitoneally, intranasally, dermally, by intravitreal injection, or by inhalation.

Citation Information

Patent Citations

  • Transdermal and trans-membrane delivery of drugs

    US5023252A